Oncotelic Therapeutics (OTLC) 10-K 14 May 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	May 08, 2020	Jun. 28, 2019
Document And Entity Information
Entity Registrant Name	MATEON THERAPEUTICS INC
Entity Central Index Key	0000908259
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-Known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 11,546,000
Entity Common Stock, Shares Outstanding		87,012,809
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash	$ 81,964	$ 2,498
Accounts receivable	149,748
Prepaid & other current assets	41,288
Total current assets	273,000	2,498
Development equipment, net of depreciation of $64,404	47,554
Long-term investment		1,769,300
Intangibles, net of accumulated amortization of $85,608 and $34,189	924,572	975,991
In process R&D	1,377,200
Goodwill	21,062,455
Total assets	23,684,781	2,747,789
Current liabilities:
Accounts payable and accrued liabilities	2,054,983
Accounts payable to related party	601,682	283,030
Contingent Consideration	2,625,000
Derivative liability on Notes	540,517
Convertible debt, related party, net of costs	16,474
Convertible debt, net of costs of	944,450
Total current liabilities	6,783,106	283,030
Commitments and contingencies (Note 11)
Stockholders' equity:
Convertible preferred stock, $0.01 par value, 15,000,000 shares authorized; 278,188 and 0 shares issued and outstanding	2,782
Common stock, $.01 par value; 150,000,000 shares authorized; 84,069,967 and 6,843,802 issued and outstanding, respectively	840,700	68,438
Additional paid-in capital	28,185,599	7,886,598
Accumulated deficit	(12,127,406)	(5,490,277)
Total stockholders' equity	16,901,675	2,464,759
Total liabilities and stockholders' equity	$ 23,684,781	$ 2,747,789

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Depreciation of development equipment	$ 64,404
Amortization of intangible assets	85,608	34,189
Convertible debt related party net of issuance cost	113,970	0
Convertible debt net of issuance cost	$ 53,052	$ 0
Convertible Preferred stock, par value	$ 0.01	$ 0.01
Convertible Preferred stock, shares authorized	15,000,000	15,000,000
Convertible Preferred stock, shares issued	278,188	0
Convertible Preferred stock, shares outstanding	278,188	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	84,069,967	6,843,802
Common stock, shares outstanding	84,069,967	6,843,802

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating expenses:
Research and development	$ 1,372,151	$ 649,755
General and administrative	2,938,726	62,983
Total operating expenses	4,310,877	712,738
Loss from operations	(4,310,877)	(712,738)
Other expense:
Interest income	123
Interest expense	(749,602)
Change in fair value of derivative on debt	191,643
Long term investment written off	(1,769,300)
Total other expense	(2,327,136)
Net Loss	$ (6,638,013)	$ (712,738)
Basic and diluted net loss per share attributable to common stock	$ (0.11)	$ (0.12)
Basic and diluted weighted average common stock outstanding	59,958,406	6,136,312

Consolidated Statement of Stock

Consolidated Statement of Stockholders' (Deficit) Equity - USD ($)	Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017		$ 58,764	$ 4,235,180	$ (4,777,539)	$ (483,595)
Balance, shares at Dec. 31, 2017		5,948,710
Common shares issued for cash		$ 600	239,400		240,000
Common shares issued for cash, shares		60,000
Common shares issued in lieu of cash for services		$ 1,880	749,999		751,878
Common shares issued in lieu of cash for services, shares		187,970
Common shares issued for product acquisition		$ 2,048	817,143		819,191
Common shares issued for product acquisition, shares		204,796
Common shares issued in lieu of investments		$ 4,423	1,764,877		1,769,300
Common shares issued in lieu of investments, shares		442,326
Stock-based compensation		$ 723	80,000		80,723
Net loss				(712,738)	(712,738)
Balance at Dec. 31, 2018		$ 68,438	7,886,598	(5,490,277)	2,464,759
Balance, shares at Dec. 31, 2018		6,843,802
Common shares issued for cash		$ 208	82,792		83,000
Common shares issued for cash, shares		20,750
Common shares issued in lieu of cash for services		$ 918	417,218		418,136
Common shares issued in lieu of cash for services, shares		91,844
Stock-based compensation			340,674		340,674
Common shares issued for settlement of accounts payable to related party		$ 808	237,282		238,090
Common shares issued for settlement of accounts payable to related party, shares		80,772
Recapitalization under reverse merger	$ 1,937	$ 752,328	$ 2,972,606	$ 884	$ 3,727,755
Recapitalization under reverse merger, shares	193,713	75,232,799
Beneficial conversion feature on convertible debt and restricted common shares		10,500	895,862		906,362
Beneficial conversion feature on convertible debt and restricted common shares, shares		1,050,000
Common shares issued in conversion of warrants		$ 1,500	$ (1,380)		$ 120
Common shares issued in conversion of warrants, shares		150,000
Acquisition of PointR	$ 845		15,239,947		15,240,792
Acquisition of PointR, shares	84,475
Derivative on debt
Common shares issued to investors		$ 6,000	114,000		120,000
Common shares issued to investors, shares		600,000
Net loss				(6,638,013)	(6,638,013)
Balance at Dec. 31, 2019	$ 2,782	$ 840,700	$ 28,185,599	$ (12,127,406)	$ 16,901,675
Balance, shares at Dec. 31, 2019	278,188	84,069,967

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net loss	$ (6,638,013)	$ (712,738)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and deferred finance costs	745,973
Amortization of intangible assets	51,419	34,189
Stock-based compensation	340,674	80,000
Depreciation on development equipment	9,238
Common shares issued to investors	120,000
Issuance of common stock in lieu of cash for services	418,136	751,878
Change in fair value of derivative	(191,643)
Write off of long term investment	1,769,300
Write off of related party accounts payable		(458,221)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(78,559)	26,147
Accounts payable and accrued expenses	616,043	37,765
Accounts payable to related party	556,742
Net cash used in operating activities	(2,280,690)	(240,980)
Cash flows from investing activities:
Cash acquired in mergers	189,286
Net cash provided by investing activities	189,286
Cash flows from financing activities:
Proceeds from sales of common stock	83,000	240,000
Net proceeds from convertible notes payable, related party	203,870
Net proceeds from convertible notes payable	1,884,000
Net cash provided by financing activities	2,170,870	240,000
Net increase (decrease) in cash	79,466	(980)
Cash - beginning of period	2,498	3,478
Cash - end of period	81,964	2,498
Supplemental cash flow information:
Cash paid for: Interest paid
Cash paid for: Income taxes paid
Non cash investing and financing activities:
Recapitalization under reverse merger	3,727,752
Acquisition of PointR	15,240,792
Issuance of common stock for settlement of accounts payable to related party	238,090	751,878
Beneficial conversion feature on convertible debt and restricted common shares	684,140
Capitalization of prepaid expenses related to product acquisition		819,191
Issuance of preferred stock for settlement of debt	204,603
Non cash investment		$ 1,769,300

Description of Business and Bas

Description of Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Description of Business Mateon Therapeutics, Inc. (f/k/a OXiGENE, Inc.) (the “Parent”, “Mateon”), was formed in the State of New York in 1988, was reincorporated in the State of Delaware in 1992 and changed its name to Mateon Therapeutics, Inc. in 2016. Mateon conducts business activities through both the Parent and its wholly-owned subsidiary Oncotelic, Inc. (“Oncotelic”), a Delaware corporation (collectively, the “Company”). Mateon is evaluating the further development of its product candidates OXi4503 as a treatment for acute myeloid leukemia and myelodysplastic syndromes and CA4P in combination with a checkpoint inhibitor for the treatment of advanced metastatic melanoma. On April 17, 2019, Mateon entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Oncotelic, a clinical-stage biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications and the Company’s wholly-owned subsidiary Oncotelic Acquisition Corporation (the “Merger Sub”). Upon the terms of and subject to the satisfaction of the conditions described in the Merger Agreement, the Merger Sub was merged with and into Oncotelic (the “Merger”), with Oncotelic surviving the Merger as a wholly-owned subsidiary of the Company. On April 22, 2019, Mateon completed the Merger and Oncotelic became a wholly-owned subsidiary of Mateon. Upon the completion of the Merger each share of Oncotelic common stock outstanding immediately prior to the Merger (excluding any shares of Oncotelic held by stockholders exercising dissenters’ appraisal rights) was converted pursuant to the Merger Agreement using the following ratios of (i) 3.97335267 shares of Mateon common stock, par value $0.01 per share (the “Common Stock”), and (ii) 0.01877292 shares of the Company’s newly designated Series A Convertible Preferred Stock (the “Series A Preferred”). Following the closing of the Merger, the former Oncotelic security holders own approximately 85% of the Company’s issued and outstanding Common Stock (including any shares of Common Stock issuable upon conversion of the Series A Preferred), and the Company’s stockholders prior to the Merger own approximately 15% of the Company’s issued and outstanding Common Stock (including any shares of Common Stock Issuable upon conversion of the Series A Preferred). The Merger was treated as a recapitalization and reverse acquisition for financial accounting purposes. Oncotelic is considered the acquirer for accounting purposes, and the registrant’s historical financial statements before the Merger have been replaced with the historical financial statements of Oncotelic prior to the Merger in the financial statements and filings with the Securities and Exchange Commission. The Company is a cancer immunotherapy company dedicated to the development of first in class self-immunization protocol (SIP™) candidates for difficult to treat cancers. The Company’s proprietary SIP™ candidates offer advantages over other immunotherapies because they do not require extraction of the tumor or isolation of the antigens, and they have the potential for broad-spectrum applicability for multiple cancer types. The Company’s proprietary product candidates have shown promising clinical activity in phase 2 trials for the treatment of gliomas and pancreatic cancers. The Company aims to translate its unique insights, which span more than three decades of original work using RNA therapeutics, into the deployment of antisense as a RNA therapeutic for diseases which are caused by TGF-beta overexpression, starting with cancer and expanding to Duchenne Muscular Dystrophy (DMD) and others. Oncotelic’s lead product candidate, OT-101, is being developed as a broad-spectrum anti-cancer drug that can also be used in combination with other standard cancer therapies to establish an effective multi-modality treatment strategy for difficult-to-treat cancers. Together, the Company plans to initiate phase 3 clinical trials for OT-101 in both high-grade glioma and pancreatic cancer; and any other indications that may evolve. The Company is also planning to develop OT-101 for the various epidemics and pandemics, similar to the current corona virus (COVID-19) pandemic. Please see Note 12 – Subsequent Events Covid-19 Efforts . On August 17, 2019, the Company entered into an Agreement and Plan of Merger (the “PointR Merger Agreement”) with PointR. Upon the terms of, and subject to the satisfaction of the conditions described in the PointR Merger Agreement, PointR would be merged with and into a newly formed subsidiary of the Company (the “PointR Merger Sub”), with PointR surviving the merger as a wholly-owned subsidiary of the Company. The merger is intended to create a publicly-traded artificial intelligence (“AI”) driven immuno-oncology company with a robust pipeline of first in class TGF-β immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. On November 1, 2019, the Company entered into Amendment No. 1 (the “Amendment”) to the PointR Merger Agreement with PointR. The Amendment revised certain terms of the PointR Merger Agreement to provide that holders of PointR common stock would receive shares of the Company’s Series A Preferred in lieu of the Company’s Common Stock in connection with the merger. The Amendment revised the terms of the milestones for earn-out payment as well. On November 4, 2019, pursuant to the terms of the PointR Merger Agreement the Company completed the merger with PointR. On the effectiveness of the merger, the outstanding common stock of PointR immediately prior to the merger, including the conversion of a $200,000 note with accrued interest, excluding any shares of PointR held by stockholders exercising dissenters’ appraisal rights, was converted solely into the right to receive approximately 84,475 shares of the Company’s Series A Preferred. Immediately following the closing of the Merger, the former PointR security holders own approximately 23.29% of the Company’s issued and outstanding Common Stock (including any shares of Common Stock issuable upon the conversion of the Company’s Series A Preferred), and the Company’s stockholders prior to the Merger own approximately 76.71% of the Company’s issued and outstanding Common Stock (including any shares of Common Stock issuable upon conversion of the Company’s Series A Preferred). Please review Note 12 – Subsequent events for more information on updates since December 31, 2019. Principles of Consolidation The consolidated financial statements include the accounts of Mateon and its wholly-owned subsidiaries, Oncotelic and PointR. Intercompany accounts and transactions have been eliminated in consolidation. Basis of Presentation The accompanying consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission including Form 10-K and Regulation S-X. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments) which are, in the opinion of management, necessary to fairly state the operating results for the respective periods. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) have been omitted pursuant to such rules and regulations. Liquidity and Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred net losses of approximately $12.1 million since inception, had negative working capital of $6.5 million at December 31, 2019, of which approximately $1.1 million is attributable to assumed working capital of Mateon and $2.6 million contingent liability of issuance of common shares of Mateon to PointR shareholders upon achievement of certain milestones in accordance with the merger agreement with PointR, and has negative cash flows from operations during the year ended December 31, 2019. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date of this filing. Management expects to incur additional losses in the foreseeable future and recognizes the need to raise capital to remain viable. The accompanying consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. The Company’s long-term plans include continued development of its current pipeline of products to generate sufficient revenues, through either technology transfer or product sales, to cover its anticipated expenses. Until the Company is able to generate sufficient revenues from its current pipeline, the Company plans on funding its operations through the sale of equity and/or the issuance of debt, combined with or without warrants or other equity instruments. On April 17, 2019, the Company entered into a Securities Purchase Agreement with two institutional investors for a commitment to purchase convertible debentures in the aggregate principal amount of up to $400,000. Further, on April 17, 2019, the Company entered into a Securities Purchase Agreement with our CEO and an investor (the “Bridge Investor”) for a commitment to purchase convertible debentures in the aggregate amount of up to $400,000. On April 23, 2019, the Company issued two convertible notes in the principal amount of $200,000 each, both including an original issue discount (“OID”) of $20,000 and deferred financing costs of $5,000 each, receiving net proceeds of $350,000, which were used by the Company for working capital and general corporate purposes. (Note 6). On April 23, 2019, the Company issued a convertible debenture totaling $35,556 to the Bridge Investor, including OID of $3,556, receiving net proceeds of $32,000, which were used by the Company for working capital and general corporate purposes. (Note 6) Also on April 23, 2019, the Company issued a convertible note totaling $164,444, including OID of $16,444, to our Chief Executive Officer, receiving net proceeds of $148,000, which were used by the Company for working capital and general corporate purposes. (Note 6) On June 12, 2019, the Company received the second tranche under the first Securities Purchase Agreement above. The second tranche totaled $200,000, including $20,000 OID and $1,000 of deferred financing costs, receiving net proceeds of $179,000, which is planned to be used by the Company for working capital and general corporate purposes. (Note 6) On July 22, 2019, the Company entered into a convertible note purchase agreement with PointR Data, Inc., a privately held, developer of high performance cluster computer and AI applications (“PointR”) for $200,000. The convertible note bears an interest rate of 8% per annum due on 15 th On August 6, 2019, the Company closed the second tranche of financing with our Bridge Investor, issuing an additional $200,000 face amount convertible debenture, including OID of $20,000 and $5,000 deferred financing costs, receiving net proceeds of $175,000. Following the drawdown of the second tranche from the Bridge Investor, up to $400,000 in face value of Debentures remains available under the Securities Purchase Agreement. On December 11, 2019, the Company closed its Fall 2019 Debt Financing raising an additional $500,000 for gross proceeds of $1.0 million. The transactions complete the previously announced offering, under which the Company entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with certain accredited investors for the sale of convertible promissory notes (the “Notes”). The Company completed the initial closing under the Note Purchase Agreement on November 23, 2019, issuing a $250,000 principal amount Note to each of Dr. Vuong Trieu, the Company’s Chief Executive Officer, and Stephen Boesch, in exchange for gross proceeds of $500,000. In connection with the second and final closing the Company issued Notes to additional investors including $250,000 to Dr. Sanjay Jha, the former CEO of Motorola and COO/President of Qualcomm. The Company also offset certain payables due to Dr. Vuong Trieu, the Company’s Chief Executive Officer, Chulho Park, the Company’s Chief Technology Officer, and Amit Shah, the Company’s Chief Financial Officer and converted that into the debt under the Fall 2019 Debt Financing. $35,000 due to Dr. Vuong Trieu, $27,000 due to Chulho Park and $20,000 due to Amit Shahwas converted into debt. The Company also issued notes of $168,000 to two unaffiliated accredited investors. Although no assurances can be given as to the Company’s ability to deliver on its revenue plans, or that unforeseen expenses may arise, management believes that the potential equity and debt financing or other potential financing will provide the necessary funding for the Company to continue as a going concern. Also, management cannot guarantee any potential debt or equity financing will be available on favorable terms or at all. As such, management does not believe they have sufficient cash for 12 months from the date of this report. If adequate funds are not available on acceptable terms, or at all, the Company will need to curtail operations, or cease operations completely.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions and disclosure of contingent liabilities at the date of the financial statements and revenues and expense during the reporting period. Actual results could materially differ from those estimates. The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of the financial statements. Significant estimates include the valuation of goodwill and intangible assets for impairment, deferred tax asset and valuation allowance, and fair value of financial instruments. Cash As of December 31, 2019, and December 31, 2018, the Company held all its cash in banks. The Company considers investments in highly liquid instruments with a maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2019 and December 31, 2018. Investment in Equity Securities Prior to the Merger, Oncotelic received Series E Preferred Shares of Adhera Therapeutics, Inc. (“Adhera”) in consideration for the issuance of Oncotelic’s common stock under various Securities Purchase Agreements (See Notes 7). The Company records its investments in equity securities initially at cost in accordance with Accounting Standards Codification (“ASC”) 321, Investments –Equity Securities (“ASC 321”). The Company subsequently marks the investments to market at each reporting period and, in accordance with ASU 2016-01, Financial Instruments – (Overall), records the unrealized gains or losses in the Statement of Operations. There were no unrealized gains or losses on investments in equity securities for the years ended December 30, 2019 or 2018. During the fourth quarter of the year ended December 31, 2019, the Company evaluated the fair value of the investment based on a recent filing by Adhera, in which Adhera describes their current financial condition including the potential to file for bankruptcy, the Company believes that the long term investment in Adhera is impaired and therefore, determined to write off the entire investment. Fair Value of Financial Instruments The carrying value of cash, accounts payable and accrued expense approximate their fair values based on the short-term maturity of these instruments. As defined in ASC 820, “Fair Value Measurements and Disclosures,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent measurement. The three levels of the fair value hierarchy defined by ASC 820 are as follows: ● Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities. ● Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars. ● Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value. As of December 31, 2018 Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Investments in Equity Securities Adhera Therapeutics – Convertible Series E Preferred Shares $ - $ - $ - $ 1,769,300 $ 1,769,300 $ - $ - $ - $ 1,769,300 $ 1,769,300 Through September 30, 2019, the Company had opined that since the Adhera Convertible Series E Preferred shares contained “full-ratchet” anti-dilution provisions, if Adhera were to issue any new common shares or derivative securities convertible into shares of common stock at a price that is lower than the conversion price for the Convertible Series E Preferred Stock (other than certain limited exempt issuances) then the conversion price for the Convertible Series E Preferred Stock would have automatically adjusted to the lower conversion price, as defined in the agreement with Adhera. The Adhera Convertible Series E Preferred shares are not publicly traded and there are no freely observable inputs from objective sources. During the fourth quarter of the year ended December 31, 2019, the Company evaluated the fair value of the investment based on a recent filing by Adhera, in which Adhera describes their current financial condition including the potential to file for bankruptcy, the Company believes that the long term investment in Adhera is impaired and therefore, determined to write off the entire investment. The change in the value of the investment, under level 3 of the Fair Value Measurement, is shown as under: Year ended December 31, 2019 December 31, 2018 Opening Balance $ 1,769,300 $ - Value introduced - 1,769,300 Write off value of investment (1,769,300 ) - Closing balance $ - $ 1,769,000 Net Loss Per Share Basic net loss per common share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share includes the effect of common stock equivalents (notes convertible into common stock, stock options and warrants) when, under either the treasury or if-converted method, such inclusion in the computation would be dilutive. The following number of shares have been excluded from diluted loss since such inclusion would be anti-dilutive: Year ended December 31, 2019 December 31, 2018 Convertible notes 10,000,000 - Stock options 6,145,044 6,785,617 Warrants 19,515,787 24,380,893 Potentially dilutive securities 35,660,831 31,166,510 Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees, including employee stock options, in the statements of operations. For stock options issued to employees and members of the board of directors for their services, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised. Pursuant to ASU 2018-07 Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, the Company accounts for stock options issued to non-employees for their services in accordance with ASC 718. The Company uses valuation methods and assumptions to value the stock options that are in line with the process for valuing employee stock options noted above. Impairment of Long-Lived Assets The Company reviews long-lived assets, including definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows or appraised values, depending on the nature of the assets. For the years ended December 31, 2019 and 2018, there were no impairment losses recognized for long-lived assets. Intangible Assets The Company records its intangible assets at cost in accordance with ASC 350, Intangibles – Goodwill and Other. The Company reviews the intangible assets for impairment on an annual basis or if events or changes in circumstances indicate it is more likely than not that they are impaired. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. If the review indicates the impairment, an impairment loss would be recorded for the difference of the value recorded and the new value. For the years ended December 31, 2019 and 2018, there were no impairment losses recognized for intangible assets. Goodwill Goodwill represents the excess of the purchase price of acquired business over the estimated fair value of the identifiable net assets acquired. Goodwill is not amortized but is tested for impairment at least once annually, at the reporting unit level or more frequently if events or changes in circumstances indicate that the asset might be impaired. The goodwill impairment test is applied by performing a qualitative assessment before calculating the fair value of the reporting unit. If, on the basis of qualitative factors, it is considered not more likely than not that the fair value of the reporting unit is less than the carrying amount, further testing of goodwill for impairment would not be required. Otherwise, goodwill impairment is tested using a two-step approach. The first step involves comparing the fair value of the reporting unit to its carrying amount. If the fair value of the reporting unit is determined to be greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount is determined to be greater than the fair value, the second step must be completed to measure the amount of impairment, if any. The second step involves calculating the implied fair value of goodwill by deducting the fair value of all tangible and intangible assets, excluding goodwill, of the reporting unit from the fair value of the reporting unit as determined in step one. The implied fair value of the goodwill in this step is compared to the carrying value of goodwill. If the implied fair value of the goodwill is less than the carrying value of the goodwill, an impairment loss equivalent to the difference is recorded. For the years ended December 31, 2019 and 2018, there were no impairment losses recognized for Goodwill. Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 815 “Derivatives and Hedging”. ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur, and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of Conventional Convertible Debt Instrument.” The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with ASC 470-20 “Debt – Debt with Conversion and Other Options.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Original issue discounts under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. ASC 815-40 “Derivatives and Hedging – Contracts in Entity’s Own Equity” provides that, among other things, generally, if an event is not within the entity’s control could or require net cash settlement, then the contract shall be classified as an asset or a liability. Research & Development Costs In accordance with ASC 730-10-25 “Research and Development”, research and development costs are charged to expense as and when incurred. Prior Period Reclassifications Certain amounts in prior periods may have been reclassified to conform with current period presentation. Recent Accounting Pronouncements In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The new guidance requires only a one-step quantitative impairment test, whereby a goodwill impairment loss will be measured as the excess of a reporting period unit’s carrying amount over its fair value (not to exceed the total goodwill allocated to that reporting unit). It eliminates Step 2 of the current two-step goodwill impairment test, under which a goodwill impairment loss is measured by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. ASU 2017-04 is effective for annual periods beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The adoption of ASU 2017-04 is not expected to have a material impact on the Company’s financial statements and related disclosures. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments”. The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for annual periods beginning after December 15, 2018. Early adoption is permitted, provided that all of the amendments are adopted in the same period. The guidance requires application using a retrospective transition method. The adoption of ASU 2016-15 did not have a material impact on the Company’s financial statements and related disclosures. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which defers the effective date of ASU 2014-09 for all entities by one year. ASU 2014-09 became effective for the Company on January 1, 2018. The ASU also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The Company did not have any revenues for the years ended December 31, 2019 and 2018 respectively, and may not have revenues in the near future. The adoption of ASC 606 is not likely to have any impact on the Company’s financial statements and related disclosures. On February 25, 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new guidance establishes the principles to report transparent and economically neutral information about the assets and liabilities that arise from leases. The new guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The adoption of ASU 2016-02 did not have a material impact on the Company’s financial statements and related disclosures as the Company does not have any leases. All other newly issued but not yet effective accounting pronouncements have been deemed to be not applicable or immaterial to the Company.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
Acquisitions	NOTE 3 - ACQUISITIONS Merger Agreement with Oncotelic, Inc. Effective April 22, 2019, the Company completed the Merger pursuant to the Merger Agreement. Pursuant to the terms of the Merger Agreement, Oncotelic, Inc. merged with and into Merger Sub. Oncotelic, Inc. was the surviving corporation and, as a result of the Merger, became a wholly owned subsidiary of Mateon. On the effectiveness of the Merger it is reflected that: ● for all bookkeeping and accounting purposes, the closing of the Merger (the “Closing”) was to be deemed to have occurred at 10:00 am local time on April 22, 2019; ● for the purposes of calculating the number of shares of the Company’s Common Stock, $0.01 par value per share, to be issued in exchange for common equity units of Oncotelic, Inc. in connection with the Merger, the conversion ratio was to be 3.97335267 for Common Stock and 0.01877292 of newly designated Series A Preferred; ● 41,419,934 shares of Mateon Common Stock were issued and outstanding as of the date of the Merger; ● Oncotelic’s outstanding 10,318,746 shares of Common Stock, consisting of 7,866,335 outstanding shares of Common Stock, 3,102,411 converted options and 150,000 converted warrants, that were exchanged for an aggregate of (a) 41,000,033 shares of the Company’s Common Stock and (b) 193,713 shares of the Company’s newly designated Series A Preferred, par value $0.01 per share each of which are initially convertible into 1,000 shares of Common Stock upon (i) optional conversion by the holder at any time, or (ii) mandatory conversion upon the availability of a sufficient number of authorized but unissued Common Stock. Included in the shares issued to the former stockholders of Oncotelic are approximately 2.1 million shares of Common Stock and approximately 10,000 shares of the Series A Preferred which are to be issued subject to the holders’ waiver of dissenter’s rights. ● Holders of the Company’s Common Stock at the close of business on the date prior to the effectiveness of the Merger were issued a Contingent Value Right (“CVR”). Each CVR provides its holder the right to receive 75% of the net proceeds received from the full or partial sale, license, transfer or other disposition of the intellectual property rights and related assets of the Company’s product candidates OXi4503 and CA4P, in their form and for their contemplated uses at the time of Closing, that occurs under a definitive agreement executed prior to the fourth anniversary of the Merger (after the initial $500,000 of such net proceeds, which will be retained by the Company). The CVRs are not transferable, do not entitle the holder to any equity interest in the Company and do not have any voting or dividend rights. Immediately following the Merger, Mateon had 82,419,967 shares of Common Stock issued and outstanding and 193,713 shares of Series A Preferred which when converted at a 1:1,000 ratio will result in an additional 193,712,995 shares of Common Stock. The pre-Merger stockholders of Mateon retained an aggregate of 41,419,934 shares of Common Stock of Mateon, representing approximately 15% ownership of the post-Merger company. Therefore, upon consummation of the Merger, there was a change in control of Mateon, with the former owners of Oncotelic effectively acquiring control of Mateon. The Merger has been treated as a recapitalization and reverse acquisition for financial accounting purposes. As such, Oncotelic is considered the acquirer for financial accounting purposes, and the registrant’s historical financial statements of the Company before the Merger has been replaced with the historical financial statements of Oncotelic before the Merger in the financial statements and filings with the Securities and Exchange Commission. The Company obtained a 3 rd The following table summarizes the allocation of the purchase price to the fair values of the assets acquired and liabilities assumed as of the transaction date: Cash $ 182,883 Prepaid expense 56,175 Accounts payable and other current liabilities assumed (1,391,302 ) Net liability acquired (1,152,244 ) Goodwill (a.) 4,879,999 Total purchase price (b.) $ 3,727,755 a. The primary items that generate goodwill include the value of the synergies between the acquired company and Oncotelic, Inc. and the acquired assembled workforce, neither of which qualifies for recognition as an intangible asset. Goodwill is the excess of the purchase price over the fair value of the underlying net tangible and identifiable intangible assets. In accordance with applicable accounting standards, goodwill is not amortized but instead is tested for impairment at least annually or more frequently if certain indicators are present. Goodwill and intangibles is not deductible for tax purposes. The Company has considered the valuation as a preliminary allocation of assets and liabilities and may adjust such estimates in the future, if deemed material. b. The total purchase price of $3,727,755 represents the consideration transferred from Mateon in the Merger and was calculated based on the number of shares of Common Stock outstanding at the date of the Merger. Merger with PointR On August 17, 2019, the Company entered into an Agreement and Plan of Merger (the “PointR Merger Agreement”) with PointR. Upon the terms of, and subject to the satisfaction of the conditions described in, the PointR Merger Agreement, PointR would be merged with and into a newly formed subsidiary of the Company (the “PointR Merger Sub”), with PointR surviving the merger as a wholly-owned subsidiary of the Company. The merger is intended to create a publicly-traded AI driven immuno-oncology company with a robust pipeline of first in class TGF-β immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. On November 1, 2019, the Company entered into Amendment No. 1 (the “Amendment”) to the PointR Merger Agreement with PointR. The Amendment revised certain terms of the PointR Merger Agreement to provide that holders of PointR common stock would receive shares of the Company’s Series A Preferred in lieu of the Company’s Common Stock in connection with the merger. The Amendment revised the terms of the milestones for earn-out payment as well. On November 4, 2019, pursuant to the terms of the PointR Merger Agreement the Company completed the merger with PointR. On the effectiveness of the merger, the outstanding common stock of PointR immediately prior to the merger, including the conversion of a $200,000 note with accrued interest, excluding any shares of PointR held by stockholders exercising dissenters’ appraisal rights, was converted solely into the right to receive approximately 84,475 shares of the Company’s Series A Preferred. Immediately following the closing of the Merger, the former PointR security holders own approximately 23.29% of the Company’s issued and outstanding Common Stock (including any shares of Common Stock issuable upon the conversion of the Company’s Series A Preferred), and the Company’s stockholders prior to the Merger own approximately 76.71% of the Company’s issued and outstanding Common Stock (including any shares of Common Stock issuable upon conversion of the Company’s Series A Preferred). The Company obtained a preliminary 3 rd The purchase price of approximately $17.8 million, includes $15.2 million represents the consideration transferred from Mateon at the time of the merger transaction and $2.6 million of contingent consideration issuable upon PointR achieving certain milestones. Mateon issued 84,475 shares of preferred stock of the Company, related to the $15 million of consideration and including $0.2 million of short term debt repaid by Mateon inclusive of accrued interest thereon, and convertible at a rate of 1,000 shares of common stock per preferred stock, and was calculated based on the purchase prices divided by the price of the common stock of Mateon and does not include the $2.6 million of contingent consideration. The number of shares of common stock equivalents Mateon issued to PointR stockholders, for purposes of this Annual Report on Form 10-K, is calculated pursuant to the terms of the Merger Agreement based on Mateon common stock outstanding as of November 4, 2019, as follows: $15,205,473 divided by $0.18 = 84,474,854 shares of common stock 84,474,854 shares of common stock divided by 1000 = 84,475 shares of preferred stock Combined ownership of common stock equivalents = 360,638,491 shares PointR’s ownership of combined common stock equivalents = 23.29% The application of the acquisition method of accounting is dependent upon certain valuations and other studies, which was completed in February 2020. The purchase price allocation was adopted and the final amounts allocated to assets acquired and liabilities assumed. The following table summarizes the allocation of the purchase price to the fair values of the assets acquired and liabilities assumed as of the transaction date: Assets and Liabilities Acquired: Cash $ 6,403 Fixed Assets 56,792 Other assets assumed (excluding cash and fixed assets) 260,905 In-process research and development 1,377,200 Liabilities assumed (17,964 ) Net assets acquired 1,683,336 Goodwill 16,182,456 Purchase price $ 17,865,792 a. The primary items that generate goodwill include the value of the synergies between the acquired company and PointR and the acquired assembled workforce, neither of which qualifies for recognition as an intangible asset. Goodwill is the excess of the purchase price over the fair value of the underlying net tangible and identifiable intangible assets. In accordance with applicable accounting standards, goodwill is not amortized but instead is tested for impairment at least annually or more frequently if certain indicators are present. Goodwill and intangibles is not deductible for tax purposes. The Company has considered the valuation as a preliminary allocation of assets and liabilities and may adjust such estimates in the future, if deemed material. b. The total purchase price of $17,831,427 represents the consideration transferred from Mateon in the Merger and was calculated based on the number of shares of Common Stock plus the preferred shares outstanding but convertible into Common Stock outstanding at the date of the Merger and includes $2,625,000 of contingent consideration of shares issuable to PointR shareholders upon achievement of certain milestones.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	NOTE 4 - INTANGIBLE ASSETS AND GOODWILL Mateon completed a Merger with Oncotelic (Note 3), which gave rise to Goodwill of $4,751,055. Further, we added goodwill of $16,311,400 upon the completion of the Merger with PointR (Note 3). In general, the goodwill is tested on an annual impairment date chosen of December 31. However, since both mergers were completed in 2019 and both assets are currently being developed for various cancer and COVID-19 therapies, we do not believe the goodwill of the companies acquired has been impaired. Assignment and Assumption Agreement with Autotelic, Inc. In April 2018, Oncotelic entered into an Assignment and Assumption Agreement (the “Assignment Agreement”) with Autotelic Inc., an affiliate company, and Autotelic LLC, an affiliate company, pursuant to which Oncotelic acquired the rights to all intellectual property (“IP”) related to a patented product. As consideration for the Assignment Agreement, Oncotelic issued 204,798 shares of its Common Stock for a value of $819,191. The Assignment Agreement also provides that Oncotelic shall be responsible for all costs related to the IP, including development and maintenance, going forward. All previous pass through charges related to this asset from Autotelic Inc. to Autotelic, LLC and then to Oncotelic will be null and void. As a result, Oncotelic wrote-off approximately $458,000 in previously billed charges related to the Oncotelic IP for the year ended December 31, 2018 which was recorded in general and administrative expense. Dr. Trieu, a related party, is a control person in Autotelic LLC and Autotelic Inc. Intangible Asset Summary The following table summarizes the balances as of December 31, 2019 and December 31, 2018, of the intangible assets acquired, their useful life, and annual amortization: December 31, 2019 Remaining Estimated Intangible asset – Intellectual Property $ 819,191 18.68 Intangible asset – Capitalization of license cost 190,989 18.68 1,010,180 Less Accumulated Amortization (85,608 ) Total $ 924,572 December 31, 2018 Remaining Estimated Intangible asset – Intellectual Property $ 819,191 19.27 Intangible asset – Capitalization of license cost 190,989 19.27 1,010,180 Less Accumulated Amortization (34,189 ) Total $ 975,991 Amortization of identifiable intangible assets for the years ended December 31, 2019 and 2018 was $51,365 and $34,189, respectively. The future yearly amortization expense over the next five years and thereafter are as follows: For the year ended December 31, 2020 $ 51,365 2021 51,365 2022 51,365 2023 51,365 2024 51,365 Thereafter 667,747 $ 924,572 In-Process Research & Development (IPR&D) Summary The following table summarizes the balances as of December 31, 2019 of the IPR&D assets acquired. The Company will evaluate, on an annual basis, for any impairment and record an impairment if identified. No similar balances were present in 2018: December 31, 2019 Intangible asset – In-process research & development $ 1,377,200 Total $ 1,377,200

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expense consists of the following amounts: December 31, 2019 December 31, 2018 Accounts payable $ 1,793,033 $ - Accrued expense 261,950 - $ 2,054,983 $ - December 31, 2019 December 31, 2018 Accounts payable – related party $ 601,682 $ 283,030

Convertible Debentures and Note

Convertible Debentures and Notes	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Convertible Debentures and Notes	NOTE 6 – CONVERTIBLE DEBENTURES AND NOTES As of December 31, 2019, convertible debentures and notes, net of debt discount, consist of the following amounts: December 31, 2019 10% Convertible note payable, due April 23, 2022 – Peak One 115,623 10% Convertible note payable, due June 12, 2022 – Peak One (81,735 ) 10% Convertible note payable, due April 23, 2022 - TFK 115,623 10% Convertible note payable, due April 23, 2022 – Related Party (12,663 ) 10% Convertible note payable, due April 23, 2022 – Bridge Investor (2,748 ) 10% Convertible note payable, due August 6, 2022 – Bridge Investor 26,824 $ 160,924 The gross principal balances on the convertible debentures listed above totaled $1,000,000 and included an initial debt discount totaling $800,140. Total amortization expense related to these debt discounts was $155,644 for the year ended December 31, 2019. No similar expense was recorded in the same period of 2018. The total unamortized debt discount at December 31, 2019, was $1,039,076 after recording the transactions for the derivative feature on the debt that converted to variable instruments. The Peak One Tranche #2 note and the notes issued to our CEO and the bridge investors reached the 180 days During the 3 months ended December 31, 2019. As such, Peak One, the CEO and the bridge investor had the ability to convert that debt into equity at the variable conversion price of 65% % of the Company’s lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company’s traded stock price under certain circumstances. This gave rise to a derivative feature within the debt instrument. The Company evaluated the impact of the derivative and recorded a derivative liability of $541,000. This also required the company to fully amortize the beneficial conversion feature of $563,000, record a debt discount of $169,000 and a change in fair value of $192,000 to appropriately record the transactions. Bridge Financing Peak One Financing On April 17, 2019, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Peak One Opportunity Fund, L.P. (the “Buyer”, “Peak One”), for a commitment to purchase convertible notes in the aggregate amount of $400,000, pursuant to which, for an aggregate purchase price of $400,000, the Buyer purchased (a) Tranche #1 in the form of a Convertible Promissory Note in the principal amount of $200,000 (the “Convertible Note”) and (b) 350,000 restricted shares of the Company’s Common Stock (the “Shares”) (the “Purchase and Sale Transaction”). The Company used the net proceeds from the Purchase and Sale Transaction for working capital and general corporate purposes. The Convertible Note has a principal balance of $200,000, including a 10%$ OID of $20,000 and $5,000 in debt issuance costs, receiving net proceeds of $175,000, with a maturity date of April 23, 2022. Upon the occurrence of certain events of default, the Buyer, amongst other remedies, has the right to charge a penalty in a range of 18% to 40% dependent on the specific default event. Amounts due under the Convertible Note may also be converted into shares (the “Tranche #1 Conversion Shares”) of the Company’s Common Stock at any time, at the option of the holder, at (i) a conversion price, during the first 180 days, of $0.10 per share (the “Fixed Price”), and then (2) at the lower of the Fixed Price or 65% of the Company’s lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company’s traded stock price under certain circumstances. The Company has agreed to at all times, reserve and keep available out of its authorized Common Stock a number of shares equal to at least two times the full number of the Tranche #1 Conversion Shares. The Company may redeem the Convertible Note at rates of 110% to 140% over the principal balance dependent on certain events and redeem the value with accrued interest thereon, if any. The issuance of the Convertible Note resulted in a discount from the beneficial conversion feature totaling $84,570, including $52,285 related to the beneficial conversion feature and a discount from the issuance of restricted stock of 350,000 shares for $32,285. Total amortization of these OID and debt issuance cost discounts totaled $25,193 for the year ended December 31, 2019. Total unamortized discount on this note was $84,377 as of December 31, 2019. On June 12, 2019, the Company entered into an amendment of the Purchase Agreement (“Amendment #1”) in connection with the draw-down of the second tranche, and to provide for additional borrowing capacity under that agreement. Amendment #1 increased the borrowing amount up to $600,000, adding the ability to borrow an additional $200,000 in a third tranche. On June 12, 2019, the Buyer purchased Convertible Note Tranche #2 (“Tranche #2”) totaling $200,000, including a 10% OID of $20,000 and a $1,000 debt issuance cost, receiving net proceeds of $179,000 against the April 17, 2019, Purchase Agreement with Peak One, with a maturity date of June 12, 2022. Amounts due under Tranche #2 are convertible at the same terms as Tranche #1 above. The issuance of Tranche #2 resulted in a discount from the beneficial conversion feature totaling $180,000, including $132,091 related to the conversion feature and a discount from the issuance of restricted stock of 350,000 shares for $47,909. Total amortization of these OID and debt issuance cost discounts totaled $37,046 for the year ended December 31, 2019. Total unamortized discount on this note was $163,954 as of December 31, 2019. On November 5, 2019, the Company and Peak One amended the Convertible Note under Tranche #1 to extend the date of conversion of the Convertible Note into Common Stock of the Company at 65% of the traded price of the Company’s Common Stock until January 8, 2020. This amendment put a temporary hold on Peak One to convert the debt under Tranche 1. This restriction did not apply if Peak One opted to convert the Convertible Note at $0.10. The Company compensated Peak One 300,000 shares of the Company’s Common Stock for delaying the conversion until January 18, 2020. Such shares were issued to Peak One on November 14, 2019. Non-cash compensation expense of $60,000 was recorded for such issuance. Subsequent to December 31, 2019, Peak One converted approximately $150,000 of their total debt into 2,012,145 shares of Mateon. TFK Financing On April 23, 2019, the Company, entered into a Convertible Note (the “TFK Note”) with TFK Investments, LLC (“TFK”). The TFK Note has a principal balance of $200,000, including a 10% OID of $20,000 and $5,000 in debt issuance costs, receiving net proceeds of $175,000, with a maturity date of April 23, 2022. Upon the occurrence of certain events of default, the Buyer, amongst other remedies, has the right to charge a penalty in a range of 18% to 40% dependent on the specific default event. Amounts due under the Convertible Note may also be converted into shares (the “TFK Conversion Shares”) of the Company’s Common Stock at any time, at (i) a conversion price, during the first 180 days, of $0.10 per share (the “Fixed Price”), and then (2) at the lower of the Fixed Price or 65% of the Company’s lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company’s traded stock price under certain circumstances. The Company has agreed to at all times reserve and keep available out of its authorized Common Stock a number of shares equal to at least two times the full number of the TFK Conversion Shares. The Company may redeem the Convertible Note at rates of 110% to 140% rates over the principal balance dependent on certain events and redeem the value with accrued interest thereon, if any. The issuance of the TFK Note resulted in a discount from the beneficial conversion feature totaling $84,570, including $52,285 related to the beneficial conversion feature and a discount from the issuance of restricted stock of 350,000 shares for $32,285. Total amortization of these OID and debt issuance cost discounts totaled $25,193 for the year ended December 31, 2019. Total unamortized discount on this note was $84,377 as of December 31, 2019. On November 5, 2019, the Company and TFK amended the TFK Convertible Note to extend the date of conversion of the Convertible Note into Common Stock of the Company at 65% of the traded price of the Company’s Common Stock until January 8, 2020. This restriction did not apply if TFK wished to convert the Convertible Note at $0.10 per share. The Company compensated TFK 300,000 shares of the Company’s Common Stock for delaying the conversion until January 8, 2020. Such shares were issued to TFK on November 14, 2019. Non-cash compensation expense of $60,000 was recorded for such issuance. Subsequent to December 31, 2019, TFK converted $133,430 of their total debt into 1,950,000 shares of Mateon. Notes with Officer and Bridge Investor On April 17, 2019, the Company entered into a Securities Purchase Agreement (the “Bridge SPA”) with our CEO and the Bridge Investor with a commitment to purchase convertible notes in the aggregate of $400,000. On April 23, 2019, the Company entered into a convertible note with our Chief Executive Officer, Vuong Trieu, Ph. D. (the “Trieu Note”). The Trieu Note has a principal balance of $164,444, including a 10% OID of $16,444, resulting in net proceeds of $148,000, with a maturity date of April 23, 2022. Upon the occurrence of certain events of default, the Buyer, amongst other remedies, has the right to charge a penalty in a range of 18% to 40% dependent on the specific default event. Amounts due under the Convertible Note may also be converted into shares (the”Trieu Conversion Shares”) of the Company’s Common Stock at any time, at the option of the holder, at a conversion price of $0.10 per share (the “Fixed Price”), at the lower of the Fixed Price or 65% of the Company’s lowest traded price after the 180 th The issuance of the Trieu Note resulted in a discount from the beneficial conversion feature totaling $131,555 related to the conversion feature. Total amortization of the 10% OID discount totaled $34,029 for the year ended December 31, 2019. Total unamortized discount on this note was $113,970 as of December 31, 2019. On April 23, 2019, pursuant to the Bridge SPA the Company entered into Convertible Note Tranche #1 (“Tranche #1”) with the Bridge Investor. Tranche #1 has a principal balance of $35,556, an OID of $3,556, resulting in net proceeds of $32,000, with a maturity date of April 23, 2022. Upon the occurrence of certain events of default, the Buyer, amongst other remedies, has the right to charge a penalty in a range of 18% to 40% dependent on the specific default event. Amounts due under Tranche #1 may also be converted into shares (the “Bridge SPA Conversion Shares”) of the Company’s Common Stock at any time, at (i) a conversion price, during the first 180 days, of $0.10 per share (the “Fixed Price”), and then (2) at the lower of the Fixed Price or 65% of the Company’s lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company’s traded stock price under certain circumstances. The Company may redeem the Convertible Note at rates of 110% to 140% rates over the principal balance dependent on certain events and redeem the value with accrued interest thereon, if any. The issuance of the note resulted in a discount from the beneficial conversion feature totaling $28,445. Total amortization of the OID and discount totaled $7,358 for the year ended December 31, 2019. Total unamortized discount on this note was $24,643 as of December 31, 2019. On August 6, 2019, pursuant to the Bridge SPA the Company entered into Convertible Note Tranche #2 (“Tranche #2”) with the Bridge Investor. Tranche #2 has a principal balance of $200,000, an OID of $20,000 and debt issuance costs of $5,000, resulting in net proceeds of $175,000, with a maturity date of August 6, 2022. Upon the occurrence of certain events of default, the Buyer, amongst other remedies, has the right to charge a penalty in a range of 18% to 40% dependent on the specific default event. Amounts due under Tranche #1 may also be converted into shares (the “Bridge SPA Conversion Shares”) of the Company’s Common Stock at any time, at the option of the holder, at a conversion price of $0.10 per share (the “Fixed Price”), at the lower of the Fixed Price or 65% of the Company’s lowest traded price after the 180 th The issuance of the note resulted in a discount from the beneficial conversion feature totaling $175,000. Total amortization of the OID and discount totaled $26,825 for the year ended December 31, 2019. Total unamortized discount on this note was $173,175 as of December 31, 2019. The Peak One Tranche #2 note and the notes issued to our CEO and the bridge investors reached the 180 days During the 3 months ended December 31, 2019. As as such, Peak One, the CEO and the bridge investor had the ability to convert that debt into equity at the variable conversion price of 65% % of the Company’s lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company’s traded stock price under certain circumstances. This gave rise to a derivative feature within the debt instrument. The Company evaluated the impact of the derivative and recorded a derivative liability of approximately $541,000. This also required the company to fully amortize the beneficial conversion feature of approximately $563,000, record a debt discount of approximately $169,000 and a change in fair value of approximately $192,000 to appropriately record the transactions. Convertible Note with PointR Data, Inc. On July 22, 2019, the Company entered into a Note Purchase Agreement with PointR. Pursuant to the Note Purchase Agreement, the Company issued a Convertible Promissory Note to PointR. in the principal amount of $200,000. The Convertible Promissory Note bore interest at a rate of 8% per annum. Interest payments were due monthly on the 15th day of each calendar month (or the next business day thereafter), and were payable, at the option of the holder, either in cash or in shares of the Company’s Common Stock, valued at the closing price of the Common Stock on the principal market on which the Common Stock is either traded or quoted at such time. The Convertible Promissory Note was due and payable on demand by the holder (a) at any time after January 1, 2020 or (b) upon the occurrence of an Event of Default (as defined in the Convertible Note and the Note Purchase Agreement). All amounts outstanding under the Convertible Promissory Note would be automatically be converted into the Company’s securities issued in next equity financing raising gross proceeds of $10 million or more (a “Qualified Financing”) at the price per share paid by investors in the Qualified Financing. As the conversion feature is contingent upon a future event, the conversion feature will be evaluated under ASC 470-20 and ASC 815 when and if the Qualified Financing occurred. On November 4, 2019, the Convertible Note, with accrued interest of $4,603 thereon, was converted into Company’s Series A Preferred and is a part of the total consideration of 84,475 Series A Preferred issued to the PointR shareholders. Since the conversion occurred prior to the Qualified Financing, the Company did not have to evaluate the conversion feature under ASC 470-20 and ASC 815. Fall 2019 Debt Financing As of December 31, 2019, the amounts outstanding, inclusive of accrued interest thereon, on the Fall 2019 Debt Financing consisted of: December 31, 2019 5% Convertible note payable – Stephen Boesch 187,785 5% Convertible note payable – Vuong Trieu* 187,785 5% Convertible note payable – Sanjay Jha (Through his family trust) 187,785 5% Convertible note payable – CEO, CTO & CFO 77,620 5% Convertible note payable – Bridge Investors 159,025 $ 800,000 *There was an amount of $130,000 due for the Note from Dr. Trieu as of December 31, 2019. Such amount was received by the Company during the three months ended March 31, 2020. On December 11, 2019, the Company closed its Fall 2019 Debt Financing raising an additional $500,000 for gross proceeds of $1.0 million. The Company entered into Note Purchase Agreements (the “Note Purchase Agreements”) with certain accredited investors for the sale of convertible promissory notes (the “Fall 2019 Notes”). The Company completed the initial closing under the Note Purchase Agreements on November 23, 2019, issuing a $250,000 principal amount Fall 2019 Note to each of Dr. Vuong Trieu, the Company’s Chief Executive Officer, and Stephen Boesch, in exchange for gross proceeds of $500,000. In connection with the second and final closing the Company issued the Fall 2019 Notes to additional investors including $250,000 to Dr. Sanjay Jha, through his family trust, the former CEO of Motorola and COO/President of Qualcomm. The Company also offset certain amounts due to Dr. Vuong Trieu, the Company’s Chief Executive Officer, Chulho Park, the Company’s Chief Technology Officer, and Amit Shah, the Company’s Chief Financial Officer and converted such amounts due into the Fall 2019 Notes. $35,000 due to Dr. Vuong Trieu, $27,000 due to Chulho Park and $20,000 due to Amit Shah was converted into debt. The Company also issued the Fall 2019 Notes of $168,000 to two unaffiliated accredited investors. All the Fall 2019 Notes provide for interest at the rate of 5% per annum, and are unsecured. All amounts outstanding under the Fall 2019 Notes become due and payable upon the approval of the holders of a majority of the principal amount of outstanding Fall 2019 Notes (the “Majority Holders”) on or after (a) November 23, 2020 or (b) the occurrence of an event of default (either, the “Maturity Date”). The Company may prepay the Fall 2019 Notes at any time. Events of default under the Fall 2019 Notes include failure to make payments under the Fall 2019 Notes within thirty (30) days of the date due, failure to observe of the Note Purchase Agreement or Fall 2019 Notes which is not cured within thirty (30) days of notice of the breach, bankruptcy, or a change in control of the Company (as defined in the Note Purchase Agreement). The Majority Holders have the right, at any time not more than five (5) days following the Maturity Date, to elect to convert all, and not less than all, of the outstanding accrued and unpaid interest and principal on the Fall 2019 Notes. The Fall 2019 Notes may be converted, at the election of the Majority Holders, either (a) into shares of the Company’s Common Stock at a conversion price of $0.18 per share, or (b) into shares of EdgePoint’s, the Company’s to be newly formed subsidiary for AI/Blockchain in pharmaceutical manufacturing, common stock at a conversion price of $5.00 (based on a $5 million pre-money valuation) of EdgePoint and 1 million shares outstanding. The issuance of the Fall 2019 notes resulted in a discount from the beneficial conversion feature totaling $222,222 related to the conversion feature. Total amortization of the discount totaled $22,222 for the year ended December 31, 2019. Total unamortized discount on this note was $200,000 as of December 31, 2019. Further, the Company recorded interest expense of $3,869 on these Fall 2019 Notes for the year ended December 31, 2019. The total amount outstanding under the Fall 2019 Notes, including accrued interest thereon, as of December 31, 2019 was $1,003,869.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 7 - RELATED PARTY TRANSACTIONS Master Service Agreement with Autotelic Inc. In October 2015, Oncotelic entered into a Master Service Agreement (the “MSA”) with Autotelic Inc., a related party that is partly-owned by the Company’s CEO Vuong Trieu, Ph.D. Dr. Trieu, a related party, is a control person in Autotelic Inc. Autotelic Inc. currently owns less than 10% of the Company. The MSA stated that Autotelic Inc. will provide business functions and services to the Company and allowed Autotelic Inc. to charge the Company for these expenses paid on its behalf. The MSA includes personnel costs allocated based on amount of time incurred and other services such as consultant fees, clinical studies, conferences and other operating expenses incurred on behalf of the Company. The MSA requires a 90-day written termination notice in the event either party requires to terminate such services. Expenses related to the MSA were $1,280,737 for the year ended December 31, 2019 as compared to $1,029,439 for year ended December 31, 2018. In January 2019, Oncotelic issued a total of 80,772 shares of common stock with a fair value of $4.00 per share to Autotelic, Inc. in lieu of cash for the settlement of outstanding accounts payable. In addition, Autotelic Inc. billed the Company $48,485 for the year ended December 31, 2019 related to charges incurred on behalf of the Company. No similar charges were incurred in the same period of 2018. Stock Purchase Agreements In December 2018, Oncotelic entered into a Stock Purchase Agreement with the Company’s CEO, Vuong Trieu, Ph.D. (the “Vuong SPA”). In connection with the Vuong SPA Oncotelic issued 189,238 shares of common shares at $4.00 per share. As consideration for the shares Oncotelic received 151.39 Preferred Series E shares of Adhera Therapeutics, Inc. with a value of $756,950. In December 2018, Oncotelic entered into a Stock Purchase Agreement with Autotelic Inc. (the “Autotelic SPA”). In connection with the Autotelic SPA Oncotelic issued 226,988 shares of common shares at $4.00 per share. As consideration for the shares Oncotelic received 181.59 Preferred Series E shares of Adhera Therapeutics, Inc. with a value of $907,950. License Fee with Autotelic In December 2015, Oncotelic paid Autotelic Inc. $395,150 for the right to license the use of Trabedersen (OT-101) for 5 years. On April 13, 2018, Oncotelic purchased the license for OT-101 from Autotelic Inc. for $819,191, which was recorded as an intangible asset. In addition, the remaining prepaid expense of $191,191 was converted into an intangible to be amortized at the same rate as the license. As such, Oncotelic recorded a charge of $51,365 and $34,243 for the years ended December 31, 2019 and 2018, respectively, as amortization of the intangibles acquired. Oncotelic had approximately $924,572 and $975,991 of unamortized intangibles as of December 31, 2019 and 2018, respectively. On December 31, 2018, Oncotelic issued Autotelic Inc. 204,798 shares of the Company’s common stock as consideration for the license. Note Payable – Related Party On April 23, 2019, the Company issued a convertible note to our Chief Executive Officer totaling $164,444, including OID of $16,444, receiving net proceeds of $148,000, which was used by the Company for working capital and general corporate purposes (Note 6). In addition, the Company issued a $250,000 principal amount Fall 2019 Note to the Chief Executive Officer also offset certain amounts due to the Company’s Chief Executive Officer in the amount of $35,000 due to and was converted into debt.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Stockholders' Equity	NOTE 8 - STOCKHOLDERS’ EQUITY The following transactions affected the Company’s Stockholders’ Equity: Equity Transactions During the Period Prior to the Merger Issuance of Common Stock On December 26, 2018, Oncotelic issued 26,100 shares of common stock to a third-party investor in connection with a Share Purchase Agreement for 20.88 shares of Preferred Series E Stock of Adhera Therapeutics, Inc. with a value of $104,400. On December 26, 2018, Oncotelic entered into a Stock Purchase Agreement with the Company’s CEO, Vuong Trieu, Ph.D. (the “Vuong SPA”). In connection with the Vuong SPA, Oncotelic issued 189,238 shares of common shares at $4.00 per share. As consideration for the shares Oncotelic received 151.39 Preferred Series E shares of Adhera Therapeutics, Inc. with a value of $756,950. On December 26, 2018, Oncotelic entered into a Stock Purchase Agreement with Autotelic Inc. (the “Autotelic SPA”). In connection with the Autotelic SPA Oncotelic issued 226,988 shares of common shares at $4.00 per share. As consideration for the shares Oncotelic received 181.59 Preferred Series E shares of Adhera Therapeutics, Inc. with a value of $907,950. On January 11, 2019, Oncotelic issued 11,250 shares of common stock with a fair value of $4.00 per share to an employee in lieu of cash for compensation. In January 2019, Oncotelic issued a total of 80,772 shares of common stock with a fair value of $4.00 per share to Autotelic, Inc. in lieu of cash for the settlement of outstanding accounts payable and services received during the three months ended March 31, 2019. In January 2019, Oncotelic issued a total of 20,750 shares of common stock with a fair value of $4.00 per share to two separates investors for $83,000 in cash. In March 2019, Oncotelic issued 80,594 shares of common stock with a fair value of $4.00 per share to various employees in lieu of cash for accrued compensation. In April 2019, the Company issued a total of 150,000 shares of Common Stock to two investors as a result of the conversion of warrants for $120 in cash. Equity Transactions During the Period Since the Merger Issuance of Preferred Stock On April 22, 2019, pursuant to the Merger the Company issued 193,713 shares of Series A Preferred in exchange for 77,154 shares of Oncotelic common stock. Further, the Company issued 84,475 shares of Series A Convertible Preferred Stock to PointR in exchange of 11,135,935 shares of PointR common stock upon the consummation of the PointR merger (Note 3) Issuance of Common Stock On April 22, 2019, pursuant to the Merger the Company issued 41,000,033 shares of Common Stock in exchange for 10,318,746 shares of Oncotelic common stock. (Note 3) On April 23, 2019, the Company issued 700,000 restricted shares of its Common Stock with a fair value of $0.11 per share to two noteholders in connection with convertible notes payable. (Note 6) On June 12, 2019, the Company issued 350,000 restricted shares of its Common Stock with a fair value of $0.18 per share in connection with a convertible note payable. (Note 6) On November 18, 2019, the Company issued 300,000 restricted shares of its Common Stock to Peak One with a fair value of $0.20 to extend the date of conversion of the Convertible Note into Common Stock of the Company at 65% of the traded price of the Company’s Common Stock until January 18, 2020. This restriction did not apply if Peak One wished to convert the Convertible Note at $0.10. The Company recorded a cost of $60,000 in lieu of such issuance. On November 18, 2019, the Company issued 300,000 restricted shares of its Common Stock to TFK with a fair value of $0.20 to extend the date of conversion of the Convertible Note into Common Stock of the Company at 65% of the traded price of the Company’s Common Stock until January 8, 2020. This restriction did not apply if TFK wished to convert the Convertible Note at $0.10 per share. The Company recorded a cost of $60,000 in lieu of such issuance.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2019
Compensation Related Costs [Abstract]
Stock-Based Compensation	NOTE 9 – STOCK-BASED COMPENSATION Options Pursuant to the Merger, the Company’s Common Stock and corresponding outstanding options survived. The below information details the Company’s associated option activity pre and post merger. As of December 31, 2019, options to purchase Common Stock were outstanding under three stock option plans – the 2017 Equity Incentive Plan (the “2017 Plan”), the 2015 Equity Incentive Plan (the “2015 Plan”) and the 2005 Stock Plan (the “2005 Plan”). Under the 2017 Plan, up to 2,000,000 shares of the Company’s Common Stock may be issued pursuant to awards granted in the form of nonqualified stock options, restricted and unrestricted stock awards, and other stock-based awards. Under the 2015 and 2005 Plans, taken together, up to 7,250,000 shares of the Company’s Common Stock may be issued pursuant to awards granted in the form of incentive stock options, nonqualified stock options, restricted and unrestricted stock awards, and other stock-based awards. Employees, consultants, and directors are eligible for awards granted under the 2017 and 2015 Plans. Since the adoption of the 2015 Plan, no further awards may be granted under the 2005 Plan, although options previously granted remain outstanding in accordance with their terms. Compensation based stock option activity for qualified and unqualified stock options are summarized as follows: Weighted Average Shares Exercise Price Outstanding at December 31, 2018 6,785,617 $ 0.75 Granted/Additions - - Exercised - - Expired or canceled (640,573 ) 0.62 Outstanding at December 31, 2019 6,145,044 $ 0.75 The following table summarizes information about options to purchase shares of the Company’s Common Stock outstanding and exercisable at December 31, 2019: Weighted- Weighted- Average Average Outstanding Remaining Life Exercise Number Exercise prices Options In Years Price Exercisable $ 0.22 2,524,513 8.48 $ 0.22 2,524,513 0.38 1,162,500 7.04 0.375 1,162,500 0.51 242,966 7.45 0.51 242,966 0.58 271,224 6.82 0.58 271,224 0.73 1,025,000 6.23 0.73 1,025,000 1.37 150,000 5.56 1.37 150,000 1.43 525,000 5.41 1.43 525,000 2.60 5,280 4.51 2.60 5,280 2.79 9,760 4.01 2.79 9,760 2.95 150,000 4.38 2.95 150,000 11.88 2,359 2.01 11.88 2,359 15.00 75,000 5.41 15.00 75,000 19.80 1,442 1.84 19.80 1,442 6,145,044 7.12 $ 0.75 6,145,044 The compensation expense attributed to the issuance of the options is recognized as they are vested. The employee stock option plan stock options are exercisable for ten years from the grant date and vest over various terms from the grant date to three years. The aggregate intrinsic value totaled $0 and was based on the Company’s closing stock price of $0.19 as of December 31, 2019, which would have been received by the option holders had all option holders exercised their options as of that date. All the compensation expense was recorded prior to the close of the Merger, as the vesting of all the options was accelerated due to the effective change in control of the Company, and as such no compensation expense related to the above options was recorded during the year ended December 31, 2019 and 2018, respectively. As of December 31, 2019, there was no future compensation cost as all stock options are vested at December 31, 2019. On April 22, 2019 and in conjunction with the close of the Merger, the Company recorded approximately $341,000 in compensation cost as a result of the acceleration of the vesting schedule of approximately 328,000 Oncotelic options. Pursuant to the Merger these options were converted into Common and Series A Preferred Shares in the Company. On August 23, 2019, the Company entered into Employment Agreements and incentive compensation arrangements with each of its executive officers, including Dr. Vuong Trieu, the Chief Executive Officer; Dr. Fatih Uckun, the Chief Medical Officer; Dr. Chulho Park, its Chief Technology Officer; and Mr. Amit Shah, the Chief Financial Officer. Details of the agreements and the incentive compensation is described in detail in Note 11 – Commitments & Contingencies under “Employment Agreements”. The incentive stock options or the restricted stock awards granted to the Company’s executive officers have not been granted as of the date of this filing. Warrants Pursuant to the Merger, the Company’s Common Stock and corresponding outstanding warrants survived. The below information details represents the Company’s associated warrant activity pre-merger and post-merger. The issuance of warrants to purchase shares of the Company’s Common Stock including those attributed to debt issuances are summarized as follows: Weighted- Average Shares Exercise Price Outstanding at December 31, 2018 24,380,893 $ 1.05 Expired or cancelled (4,865,106 ) 2.82 Outstanding at December 31, 2019 19,515,787 $ 0.60 Weighted- Average Shares Exercise Price Outstanding at December 31, 2017 9,625,393 $ 2.55 Granted 16,362,500 0.38 Expired or cancelled (1,607,000 ) 3.35 Outstanding at December 31, 2018 24,380,893 $ 1.05 The following table summarizes information about warrants outstanding and exercisable at December 31, 2019: Outstanding and exercisable Weighted- Weighted- Average Average Number Remaining Life Exercise Number Exercise Price Outstanding in Years Price Exercisable $ 0.20 1,487,500 3.33 $ 0.20 1,487,500 0.40 14,875,000 0.38 0.40 14,875,000 1.71 2,919,710 0.23 1.71 2,919,710 2.13 233,577 0.22 2.13 233,577 19,515,787 0.58 $ 0.60 19,515,787 The expense attributed to the issuances of the warrants was recognized as they vested/earned. These warrants are exercisable for three to five years from the grant date. All are currently exercisable. There were no warrants issued during the year ended December 31, 2019. 16,362,500 warrants were issued during the year ended December 31, 2018.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 10 – INCOME TAXES The Company had net deferred tax assets of approximately $65 million and $1.0 million as of December 31, 2019 and 2018, respectively, which primarily relate to net operating loss carryforwards. The increase in 2019 related to the two mergers. We record a valuation allowance in the full amount of our net deferred tax assets since realization of such tax benefits has been determined by our management to be less likely than not. We have identified our federal and California state tax returns as “major” tax jurisdictions. The periods our income tax returns are subject to examination for these jurisdictions are 2015 through 2018. We believe our income 8 tax filing positions and deductions will be sustained on audit, and we do not anticipate any adjustments that would result in a material change to our financial position. Therefore, no liabilities for uncertain income tax positions have been recorded. At December 31, 2019, we had available net operating loss carry-forwards for federal income tax reporting purposes of approximately $248 million which are available to offset future taxable income. Portions of these carry-forwards will expire through 2038 if not otherwise utilized. We have not performed a formal analysis, but we believe our ability to use such net operating losses and tax credit carry-forwards is subject to annual limitations due to change of control provisions under Sections 382 and 383 of the Internal Revenue Code, which significantly impacts our ability to realize these deferred tax assets. As of the date of this filing, the Company has not filed its 2019 federal and state corporate income tax returns. The Company expects to file these documents as soon as practicable.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 11 – COMMITMENTS AND CONTINGENCIES Leases The Company had a lease for its corporate headquarters, which expired in June 2019. The lease was for a total of 5,275 square feet of office space located in South San Francisco, California. Rental expense related to that corporate headquarters was $35,772 and $35,772 for the year ended December 31, 2019 and 2018, respectively. Currently, the Company is leasing the office located at 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301 on a month-to-month basis until such time a new office is identified. Legal Claims From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. The Company is not presently a party to any legal proceedings that it currently believes, if determined adversely to the Company, would individually or taken together have a material adverse effect on the Company’s business, operating results, financial condition or cash flows. Employment Agreements On August 23, 2019, the Company entered into Employment Agreements and incentive compensation arrangements with each of its executive officers, including Dr. Vuong Trieu, the Chief Executive Officer; Dr. Fatih Uckun, the Chief Medical Officer; Dr. Chulho Park, the Chief Technology Officer; and Mr. Amit Shah, the Chief Financial Officer. On November 18, 2019, upon review of said employment agreement with Dr. Uckun, it was observed that the agreement submitted for Dr. Uckun was the incorrect document. The Employment Agreements provide for annual base salaries for each year of the term, subject to review and adjustment by the Company’s Board of Directors (the “Board”) or the Compensation Committee of the Board (“Compensation Committee”) from time to time. Each Employment Agreement provides that the executive shall be eligible for an annual discretionary cash bonus expressed as a percentage the executive’s base salary, subject to their achievement of performance targets and goals established by the Board or the Compensation Committee. The Employment Agreements provide for equity awards to each executive under the terms of the Company’s stock option plans. Each Employment Agreement provides that the executive will receive a restricted stock grant of the Company’s Common Stock, par value $0.01 per share. The Company will compensate Messrs. Trieu, Uckun, Park and Shah for the taxes actually incurred on grant of the restricted shares. The restricted stock will vest fully on the one-year anniversary of employment. As of December 31, 2019, the restricted shares have yet to be issued. The Employment Agreements also provide for grants of incentive stock options to purchase shares of the Company’s Common Stock under the Stock Plan. Such options shall vest and become exercisable after one year of employment. As of December 31, 2019, the Company these options have yet to be granted. Thereafter, each Employment Agreement contemplates that the executive will be eligible to receive a comparable annual grant of restricted shares or stock options as approved by the Board or Compensation Committee and which shall contain the customary terms and provisions of such grants generally to key executives under the Stock Plan. The initial restricted stock grants and stock option grants have been set for the executives as follows: Executive Title Restricted Stock Stock Options Vuong Trieu Chief Executive Officer 209,302 313,953 Fatih Uckun Chief Medical Officer 186,047 279,070 Chulho Park Chief Technology Officer 162,791 244,186 Amit Shah Chief Financial Officer 148,837 223,256 The incentive stock options or the restricted stock awards granted to the Company’s executive officers have not been issued as of the date of this filing. PointR Merger Consideration The total purchase price of $17,831,427 represented the consideration transferred from Mateon in the Merger and was calculated based on the number of shares of Common Stock plus the preferred shares outstanding but convertible into Common Stock outstanding at the date of the Merger and includes $2,625,000 of contingent consideration of shares issuable to PointR shareholders upon achievement of certain milestones.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	NOTE 12 – SUBSEQUENT EVENTS COVID-19 efforts Research Service Agreement between Golden Mountain Partners LLC (GMP) and Mateon Therapeutics Inc./Oncotelic Inc. (“Mateon Entities”). When COVID-19 emerged in China, Mateon and GMP contemplated a collaboration to develop drug candidates for COVID-19. Oncotelic and GMP entered into a research and services agreement (the “Agreement”) on February 3, 2020 memorializing their collaborative efforts to develop and test COVID-19 antisense therapeutics. On March 18, 2020, Mateon reported the anti-viral activity of OT-101 – its lead drug candidate currently in phase 3 testing in pancreatic cancer and glioblastoma. In an in vitro antiviral testing performed by an independent laboratory, OT-101 showed that it was highly active against COVID-19. On March 23, 2020, Mateon, Oncotelic, Inc., and GMP entered into a supplement to the Agreement (the “Supplement”) to confirm the inclusion of OT-101 within the scope of the Agreement, pending positive confirmatory testing against COVID-19. In consideration for the financial support provided by GMP for the research, pursuant to the terms of the Agreement (as amended by the Supplement) GMP is entitled to obtain certain exclusive rights to the use of the Product in the COVID Field on a global basis, and an economic interest in the use of the Product in the COVID Field including 50/50 profit sharing. As described in the Supplement, the Mateon Entities intend to license or assign intellectual property rights, including the 2020 Patent Application and any other intellectual property rights owned or controlled by the Mateon Entities relating to the Product, OXi4503 and CA4P, to a joint venture company to be established jointly between Oncotelic and GMP (or its designee), as well as providing management services and other expertise to the joint venture company; GMP intends that it (or its designee, as the case may be) shall provide funding to the joint venture company to support its development and commercial activities in the joint venture company’s territories; in each case, on terms to be agreed by the parties; and GMP shall be entitled to use its governmental relations and local expertise in Greater China to assist with coordinating the research, development and commercialization of (i) the Products in the COVID Field, (ii) the Products in the OT101 Oncology Field, (iii) OXi4503; and (iv) CA4P, in each case in Greater China. The joint venture company is intended to be owned 50% by Oncotelic and 50% by GMP (or its designee), and its principal activities shall be to research, develop, bring to market and commercialize: (i) the Products in the COVID Field on a global basis, (ii) the Products in the OT101 Oncology Field in the Licensed Territory, (iii) OXi4503 in the Licensed Territory; and (iv) CA4P in the Licensed Territory. Upon completion of due diligence by one another and subject to GMP’s satisfactory due diligence review, the parties intend to enter into written definitive agreements for the Joint Venture Transaction within the Exclusivity Period of 90 days. On April 6, 2020, the Company delivered the requisite testing results to GMP confirming the applicability and potential use of OT-101 for the treatment of COVID-19. OT-101 exhibited potent activity against both COVID-19 and SARS with a robust safety index of >500. Also, The Company has submitted a Pre-Investigational New Drug (Pre-IND) application package to the Food and Drug Administration. GMP paid the Company fees of $1.2 million for the services rendered under the agreement and supplemental agreements as well as reimbursed the Company for actual costs incurred of $0.1 million. In April 2020, Mateon also filed the IND with the FDA to permit Mateon to commence clinical trials to evaluate if OT-101 is effective to treat COVID-19. The proposed randomized, double-blind, placebo-controlled Phase 2 study is intended to evaluate the safety and efficacy of OT-101 in adult patients hospitalized with positive SARS-CoV-2 and pneumonia in the US. Provisional Patent Filing On March 18, 2020 and March 20, 2020, Oncotelic, Inc. (“Oncotelic”), a wholly-owned subsidiary of Mateon Therapeutics, Inc. (“Mateon” or the “Company”), filed three provisional patent applications on the method of use and composition of matter for the treatment of COVID-19. The filings represent the culmination of internal research programs, including efforts with our external partner, and position our antisense platforms for further development for the treatment of epidemics and pandemics. Payment Protection Program On April 21, 2020, the Company, entered into a Paycheck Protection Program Promissory Note (the “PPP Note”) with respect to a loan in the amount of $250,000 (the “PPP Loan”) from Silicon Valley Bank (the “Lender”). The PPP Loan was obtained pursuant to the Paycheck Protection Program (the “PPP”) of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration (“SBA”). The PPP Loan matures on April 21, 2022 and bears interest at a rate of 1.00% per annum. The PPP Loan is payable in 17 equal monthly payments commencing November 21, 2020. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. All or a portion of the PPP Loan may be forgiven by the SBA and the Lender upon application by the Company within 60 days but not later than 120 days after loan approval and upon documentation of expenditures in accordance with the SBA requirements. Conversion of shares by Peak One and TFK In February and March of 2020, Peak One and TFK converted $150,000 of their debt of $400,000 under the Peak One Notes for 2,012,145 shares of Mateon. As such, the balance remaining unpaid as of the date of this report is $250,000. Similarly, TFK converted $133,430 of their debt of $200,000 for 1,950,000 shares of Mateon. As such, the balance remaining unpaid is $66,570 as of the date of this report. Cancellation of 2018 warrants and issue of new warrants During the quarter ended March 31, 2020, the Company offered to cancel 14,875,000 warrants issued to certain investors, at a price of $0.40, issued in connection with the 2018 private placement in exchange for new warrants at a price of $0.20. Of the 14,875,000 warrants outstanding, 13,750,000 were exchange for new warrants.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions and disclosure of contingent liabilities at the date of the financial statements and revenues and expense during the reporting period. Actual results could materially differ from those estimates. The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of the financial statements. Significant estimates include the valuation of goodwill and intangible assets for impairment, deferred tax asset and valuation allowance, and fair value of financial instruments.
Cash	Cash As of December 31, 2019, and December 31, 2018, the Company held all its cash in banks. The Company considers investments in highly liquid instruments with a maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2019 and December 31, 2018.
Investment in Equity Securities	Investment in Equity Securities Prior to the Merger, Oncotelic received Series E Preferred Shares of Adhera Therapeutics, Inc. (“Adhera”) in consideration for the issuance of Oncotelic’s common stock under various Securities Purchase Agreements (See Notes 7). The Company records its investments in equity securities initially at cost in accordance with Accounting Standards Codification (“ASC”) 321, Investments –Equity Securities (“ASC 321”). The Company subsequently marks the investments to market at each reporting period and, in accordance with ASU 2016-01, Financial Instruments – (Overall), records the unrealized gains or losses in the Statement of Operations. There were no unrealized gains or losses on investments in equity securities for the years ended December 30, 2019 or 2018. During the fourth quarter of the year ended December 31, 2019, the Company evaluated the fair value of the investment based on a recent filing by Adhera, in which Adhera describes their current financial condition including the potential to file for bankruptcy, the Company believes that the long term investment in Adhera is impaired and therefore, determined to write off the entire investment.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying value of cash, accounts payable and accrued expense approximate their fair values based on the short-term maturity of these instruments. As defined in ASC 820, “Fair Value Measurements and Disclosures,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent measurement. The three levels of the fair value hierarchy defined by ASC 820 are as follows: ● Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities. ● Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars. ● Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value. As of December 31, 2018 Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Investments in Equity Securities Adhera Therapeutics – Convertible Series E Preferred Shares $ - $ - $ - $ 1,769,300 $ 1,769,300 $ - $ - $ - $ 1,769,300 $ 1,769,300 Through September 30, 2019, the Company had opined that since the Adhera Convertible Series E Preferred shares contained “full-ratchet” anti-dilution provisions, if Adhera were to issue any new common shares or derivative securities convertible into shares of common stock at a price that is lower than the conversion price for the Convertible Series E Preferred Stock (other than certain limited exempt issuances) then the conversion price for the Convertible Series E Preferred Stock would have automatically adjusted to the lower conversion price, as defined in the agreement with Adhera. The Adhera Convertible Series E Preferred shares are not publicly traded and there are no freely observable inputs from objective sources. During the fourth quarter of the year ended December 31, 2019, the Company evaluated the fair value of the investment based on a recent filing by Adhera, in which Adhera describes their current financial condition including the potential to file for bankruptcy, the Company believes that the long term investment in Adhera is impaired and therefore, determined to write off the entire investment. The change in the value of the investment, under level 3 of the Fair Value Measurement, is shown as under: Year ended December 31, 2019 December 31, 2018 Opening Balance $ 1,769,300 $ - Value introduced - 1,769,300 Write off value of investment (1,769,300 ) - Closing balance $ - $ 1,769,000
Net Loss Per Share	Net Loss Per Share Basic net loss per common share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share includes the effect of common stock equivalents (notes convertible into common stock, stock options and warrants) when, under either the treasury or if-converted method, such inclusion in the computation would be dilutive. The following number of shares have been excluded from diluted loss since such inclusion would be anti-dilutive: Year ended December 31, 2019 December 31, 2018 Convertible notes 10,000,000 - Stock options 6,145,044 6,785,617 Warrants 19,515,787 24,380,893 Potentially dilutive securities 35,660,831 31,166,510
Stock-Based Compensation	Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees, including employee stock options, in the statements of operations. For stock options issued to employees and members of the board of directors for their services, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised. Pursuant to ASU 2018-07 Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, the Company accounts for stock options issued to non-employees for their services in accordance with ASC 718. The Company uses valuation methods and assumptions to value the stock options that are in line with the process for valuing employee stock options noted above.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets, including definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows or appraised values, depending on the nature of the assets. For the years ended December 31, 2019 and 2018, there were no impairment losses recognized for long-lived assets.
Intangible Assets	Intangible Assets The Company records its intangible assets at cost in accordance with ASC 350, Intangibles – Goodwill and Other. The Company reviews the intangible assets for impairment on an annual basis or if events or changes in circumstances indicate it is more likely than not that they are impaired. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. If the review indicates the impairment, an impairment loss would be recorded for the difference of the value recorded and the new value. For the years ended December 31, 2019 and 2018, there were no impairment losses recognized for intangible assets.
Goodwill	Goodwill Goodwill represents the excess of the purchase price of acquired business over the estimated fair value of the identifiable net assets acquired. Goodwill is not amortized but is tested for impairment at least once annually, at the reporting unit level or more frequently if events or changes in circumstances indicate that the asset might be impaired. The goodwill impairment test is applied by performing a qualitative assessment before calculating the fair value of the reporting unit. If, on the basis of qualitative factors, it is considered not more likely than not that the fair value of the reporting unit is less than the carrying amount, further testing of goodwill for impairment would not be required. Otherwise, goodwill impairment is tested using a two-step approach. The first step involves comparing the fair value of the reporting unit to its carrying amount. If the fair value of the reporting unit is determined to be greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount is determined to be greater than the fair value, the second step must be completed to measure the amount of impairment, if any. The second step involves calculating the implied fair value of goodwill by deducting the fair value of all tangible and intangible assets, excluding goodwill, of the reporting unit from the fair value of the reporting unit as determined in step one. The implied fair value of the goodwill in this step is compared to the carrying value of goodwill. If the implied fair value of the goodwill is less than the carrying value of the goodwill, an impairment loss equivalent to the difference is recorded. For the years ended December 31, 2019 and 2018, there were no impairment losses recognized for Goodwill.
Convertible Instruments	Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 815 “Derivatives and Hedging”. ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur, and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of Conventional Convertible Debt Instrument.” The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with ASC 470-20 “Debt – Debt with Conversion and Other Options.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Original issue discounts under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. ASC 815-40 “Derivatives and Hedging – Contracts in Entity’s Own Equity” provides that, among other things, generally, if an event is not within the entity’s control could or require net cash settlement, then the contract shall be classified as an asset or a liability.
Research & Development Costs	Research & Development Costs In accordance with ASC 730-10-25 “Research and Development”, research and development costs are charged to expense as and when incurred.
Prior Period Reclassifications	Prior Period Reclassifications Certain amounts in prior periods may have been reclassified to conform with current period presentation.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The new guidance requires only a one-step quantitative impairment test, whereby a goodwill impairment loss will be measured as the excess of a reporting period unit’s carrying amount over its fair value (not to exceed the total goodwill allocated to that reporting unit). It eliminates Step 2 of the current two-step goodwill impairment test, under which a goodwill impairment loss is measured by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. ASU 2017-04 is effective for annual periods beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The adoption of ASU 2017-04 is not expected to have a material impact on the Company’s financial statements and related disclosures. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments”. The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for annual periods beginning after December 15, 2018. Early adoption is permitted, provided that all of the amendments are adopted in the same period. The guidance requires application using a retrospective transition method. The adoption of ASU 2016-15 did not have a material impact on the Company’s financial statements and related disclosures. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which defers the effective date of ASU 2014-09 for all entities by one year. ASU 2014-09 became effective for the Company on January 1, 2018. The ASU also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The Company did not have any revenues for the years ended December 31, 2019 and 2018 respectively, and may not have revenues in the near future. The adoption of ASC 606 is not likely to have any impact on the Company’s financial statements and related disclosures. On February 25, 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new guidance establishes the principles to report transparent and economically neutral information about the assets and liabilities that arise from leases. The new guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The adoption of ASU 2016-02 did not have a material impact on the Company’s financial statements and related disclosures as the Company does not have any leases. All other newly issued but not yet effective accounting pronouncements have been deemed to be not applicable or immaterial to the Company.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Schedule of Fair Value Measurements	As of December 31, 2018 Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Investments in Equity Securities Adhera Therapeutics – Convertible Series E Preferred Shares $ - $ - $ - $ 1,769,300 $ 1,769,300 $ - $ - $ - $ 1,769,300 $ 1,769,300
Schedule of Changes in Fair Value Measurements	The change in the value of the investment, under level 3 of the Fair Value Measurement, is shown as under: Year ended December 31, 2019 December 31, 2018 Opening Balance $ 1,769,300 $ - Value introduced - 1,769,300 Write off value of investment (1,769,300 ) - Closing balance $ - $ 1,769,000
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following number of shares have been excluded from diluted loss since such inclusion would be anti-dilutive: Year ended December 31, 2019 December 31, 2018 Convertible notes 10,000,000 - Stock options 6,145,044 6,785,617 Warrants 19,515,787 24,380,893 Potentially dilutive securities 35,660,831 31,166,510

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2019
Merger Agreement with Oncotelic, Inc [Member]
Schedule of Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes the allocation of the purchase price to the fair values of the assets acquired and liabilities assumed as of the transaction date: Cash $ 182,883 Prepaid expense 56,175 Accounts payable and other current liabilities assumed (1,391,302 ) Net liability acquired (1,152,244 ) Goodwill (a.) 4,879,999 Total purchase price (b.) $ 3,727,755 a. The primary items that generate goodwill include the value of the synergies between the acquired company and Oncotelic, Inc. and the acquired assembled workforce, neither of which qualifies for recognition as an intangible asset. Goodwill is the excess of the purchase price over the fair value of the underlying net tangible and identifiable intangible assets. In accordance with applicable accounting standards, goodwill is not amortized but instead is tested for impairment at least annually or more frequently if certain indicators are present. Goodwill and intangibles is not deductible for tax purposes. The Company has considered the valuation as a preliminary allocation of assets and liabilities and may adjust such estimates in the future, if deemed material. b. The total purchase price of $3,727,755 represents the consideration transferred from Mateon in the Merger and was calculated based on the number of shares of Common Stock outstanding at the date of the Merger.
PointR Merger Agreement [Member]
Schedule of Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes the allocation of the purchase price to the fair values of the assets acquired and liabilities assumed as of the transaction date: Assets and Liabilities Acquired: Cash $ 6,403 Fixed Assets 56,792 Other assets assumed (excluding cash and fixed assets) 260,905 In-process research and development 1,377,200 Liabilities assumed (17,964 ) Net assets acquired 1,683,336 Goodwill 16,182,456 Purchase price $ 17,865,792

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	12 Months Ended
	Dec. 31, 2019
Schedule of Intangible Assets	The following table summarizes the balances as of December 31, 2019 and December 31, 2018, of the intangible assets acquired, their useful life, and annual amortization: December 31, 2019 Remaining Estimated Intangible asset – Intellectual Property $ 819,191 18.68 Intangible asset – Capitalization of license cost 190,989 18.68 1,010,180 Less Accumulated Amortization (85,608 ) Total $ 924,572 December 31, 2018 Remaining Estimated Intangible asset – Intellectual Property $ 819,191 19.27 Intangible asset – Capitalization of license cost 190,989 19.27 1,010,180 Less Accumulated Amortization (34,189 ) Total $ 975,991
Schedule of Amortization of Expense for Intangible Assets	The future yearly amortization expense over the next five years and thereafter are as follows: For the year ended December 31, 2020 $ 51,365 2021 51,365 2022 51,365 2023 51,365 2024 51,365 Thereafter 667,747 $ 924,572
In Process Research and Development [Member]
Schedule of Intangible Assets	The following table summarizes the balances as of December 31, 2019 of the IPR&D assets acquired. The Company will evaluate, on an annual basis, for any impairment and record an impairment if identified. No similar balances were present in 2018: December 31, 2019 Intangible asset – In-process research & development $ 1,377,200 Total $ 1,377,200

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Expenses	Accounts payable and accrued expense consists of the following amounts: December 31, 2019 December 31, 2018 Accounts payable $ 1,793,033 $ - Accrued expense 261,950 - $ 2,054,983 $ - December 31, 2019 December 31, 2018 Accounts payable – related party $ 601,682 $ 283,030

Convertible Debentures and No_2

Convertible Debentures and Notes (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Schedule of Convertible Debentures	As of December 31, 2019, convertible debentures and notes, net of debt discount, consist of the following amounts: December 31, 2019 10% Convertible note payable, due April 23, 2022 – Peak One 115,623 10% Convertible note payable, due June 12, 2022 – Peak One (81,735 ) 10% Convertible note payable, due April 23, 2022 - TFK 115,623 10% Convertible note payable, due April 23, 2022 – Related Party (12,663 ) 10% Convertible note payable, due April 23, 2022 – Bridge Investor (2,748 ) 10% Convertible note payable, due August 6, 2022 – Bridge Investor 26,824 $ 160,924
Schedule of Accrued Interest	As of December 31, 2019, the amounts outstanding, inclusive of accrued interest thereon, on the Fall 2019 Debt Financing consisted of: December 31, 2019 5% Convertible note payable – Stephen Boesch 187,785 5% Convertible note payable – Vuong Trieu* 187,785 5% Convertible note payable – Sanjay Jha (Through his family trust) 187,785 5% Convertible note payable – CEO, CTO & CFO 77,620 5% Convertible note payable – Bridge Investors 159,025 $ 800,000 *There was an amount of $130,000 due for the Note from Dr. Trieu as of December 31, 2019. Such amount was received by the Company during the three months ended March 31, 2020.

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2019
Compensation Related Costs [Abstract]
Schedule of Compensation Based Stock Option Activity	Compensation based stock option activity for qualified and unqualified stock options are summarized as follows: Weighted Average Shares Exercise Price Outstanding at December 31, 2018 6,785,617 $ 0.75 Granted/Additions - - Exercised - - Expired or canceled (640,573 ) 0.62 Outstanding at December 31, 2019 6,145,044 $ 0.75
Schedule of Options to Purchase Shares of Common Stock Outstanding and Exercisable	The following table summarizes information about options to purchase shares of the Company’s Common Stock outstanding and exercisable at December 31, 2019: Weighted- Weighted- Average Average Outstanding Remaining Life Exercise Number Exercise prices Options In Years Price Exercisable $ 0.22 2,524,513 8.48 $ 0.22 2,524,513 0.38 1,162,500 7.04 0.375 1,162,500 0.51 242,966 7.45 0.51 242,966 0.58 271,224 6.82 0.58 271,224 0.73 1,025,000 6.23 0.73 1,025,000 1.37 150,000 5.56 1.37 150,000 1.43 525,000 5.41 1.43 525,000 2.60 5,280 4.51 2.60 5,280 2.79 9,760 4.01 2.79 9,760 2.95 150,000 4.38 2.95 150,000 11.88 2,359 2.01 11.88 2,359 15.00 75,000 5.41 15.00 75,000 19.80 1,442 1.84 19.80 1,442 6,145,044 7.12 $ 0.75 6,145,044
Schedule of Warrants Activity	The issuance of warrants to purchase shares of the Company’s Common Stock including those attributed to debt issuances are summarized as follows: Weighted- Average Shares Exercise Price Outstanding at December 31, 2018 24,380,893 $ 1.05 Expired or cancelled (4,865,106 ) 2.82 Outstanding at December 31, 2019 19,515,787 $ 0.60 Weighted- Average Shares Exercise Price Outstanding at December 31, 2017 9,625,393 $ 2.55 Granted 16,362,500 0.38 Expired or cancelled (1,607,000 ) 3.35 Outstanding at December 31, 2018 24,380,893 $ 1.05
Schedule of Warrants Outstanding and Exercisable	The following table summarizes information about warrants outstanding and exercisable at December 31, 2019: Outstanding and exercisable Weighted- Weighted- Average Average Number Remaining Life Exercise Number Exercise Price Outstanding in Years Price Exercisable $ 0.20 1,487,500 3.33 $ 0.20 1,487,500 0.40 14,875,000 0.38 0.40 14,875,000 1.71 2,919,710 0.23 1.71 2,919,710 2.13 233,577 0.22 2.13 233,577 19,515,787 0.58 $ 0.60 19,515,787

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Summary of Restricted Stock Grants and Stock Option Grants	The initial restricted stock grants and stock option grants have been set for the executives as follows: Executive Title Restricted Stock Stock Options Vuong Trieu Chief Executive Officer 209,302 313,953 Fatih Uckun Chief Medical Officer 186,047 279,070 Chulho Park Chief Technology Officer 162,791 244,186 Amit Shah Chief Financial Officer 148,837 223,256

Description of Business and B_2

Description of Business and Basis of Presentation (Details Narrative) - USD ($)	Dec. 11, 2019	Nov. 23, 2019	Nov. 04, 2019	Aug. 06, 2019	Jul. 22, 2019	Jun. 12, 2019	Apr. 23, 2019	Apr. 22, 2019	Dec. 31, 2019	Dec. 31, 2018	Apr. 17, 2019
Conversion value									$ 238,090
Net losses									(6,638,013)	$ (712,738)
Working capital									(6,500,000)
Contingent liability									2,600,000
Original issue discount									1,039,076
Deferred financing costs									53,052	0
Net proceeds from convertible debt									1,884,000
Convertible debt									$ 1,000,000
Convertible Note One [Member]
Principal amount							$ 200,000
Original issue discount							20,000
Deferred financing costs							5,000
Convertible Note Two [Member]
Principal amount							200,000
Original issue discount							20,000
Deferred financing costs							5,000
Two Convertible Note [Member]
Net proceeds from convertible debt							350,000
Convertible Debt [Member] | PointR Data, Inc [Member]
Principal amount					$ 200,000
Net proceeds from convertible debt					$ 10,000,000
Interest rate					8.00%
Maturity date					Jan. 1, 2020
Shareholders [Member]
Equity ownership percentage								15.00%
Bridge Investor [Member] | Second Traunche [Member]
Net proceeds from convertible debt				$ 175,000
Bridge Investor [Member] | Convertible Debt [Member]
Principal amount							35,556
Original issue discount							3,556
Net proceeds from convertible debt							32,000
Bridge Investor [Member] | Convertible Debt [Member] | Second Traunche [Member]
Principal amount				200,000
Original issue discount				20,000
Deferred financing costs				5,000
Bridge Investor [Member] | Convertible Debt [Member] | Maximum [Member] | Second Traunche [Member]
Remaining available amount				$ 400,000
Chief Executive Officer [Member] | Convertible Debt [Member]
Principal amount							164,444
Original issue discount							16,444
Net proceeds from convertible debt							$ 148,000
Third Party [Member] | Convertible Debt [Member]
Debt payment, description					The convertible note bears an interest rate of 8% per annum due on 15th of each month and is payable, at the option of the holder, either in cash or in shares of the Company's Common Stock
Maturity date					Jan. 1, 2020
Additional Investors with Dr. Sanjay Jha [Member]
Notes issued		$ 250,000
Two Unaffiliated Accredited Investors [Member]
Notes issued		168,000
Oncotelic [Member] | Shareholders [Member]
Equity ownership percentage								85.00%
Common Stock [Member]
Conversion of shares									80,772
Conversion value									$ 808
Net losses
Merger Agreement [Member]
Conversion of shares								10,318,746
Merger Agreement [Member] | PointR Data, Inc [Member]
Contingent liability			$ 2,625,000
Merger Agreement [Member] | Series A Convertible Preferred Stock [Member]
Conversion of shares								0.01877292
Merger Agreement [Member] | Common Stock [Member]
Conversion of shares							193,712,995	3.97335267
Conversion of shares, par value								$ 0.01
PointR Merger Agreement [Member]
Conversion of shares			84,475
Conversion value			$ 200,000
PointR Merger Agreement [Member] | Stockholders [Member]
Equity ownership percentage			23.29%
PointR Merger Agreement [Member] | Securities Holder [Member]
Equity ownership percentage			76.71%
Since Inception Date [Member]
Net losses									12,300,000
Assumed working capital									$ 1,100,000
Securities Purchase Agreement [Member] | Second Traunche [Member]
Net proceeds from convertible debt						$ 179,000
Securities Purchase Agreement [Member] | Convertible Debt [Member] | Second Tranche [Member]
Principal amount						200,000
Original issue discount						20,000
Deferred financing costs						$ 1,000
Securities Purchase Agreement [Member] | Ttwo Institutional Investors [Member]
Principal amount											$ 400,000
Securities Purchase Agreement [Member] | Bridge Investor [Member] | Convertible Debt [Member] | Maximum [Member]
Principal amount											$ 400,000
Fall 2019 Debt Financing [Member]
Principal amount	$ 500,000
Net proceeds from convertible debt	$ 1,000,000
Fall 2019 Debt Financing [Member] | Dr. Vuong Trieu [Member]
Convertible debt		35,000
Fall 2019 Debt Financing [Member] | Chulho Park [Member]
Convertible debt		27,000
Fall 2019 Debt Financing [Member] | Amit Shahwas [Member]
Convertible debt		20,000
Note Purchase Agreement [Member] | Dr. Vuong Trieu [Member]
Principal amount		250,000
Net proceeds from convertible debt		500,000
Note Purchase Agreement [Member] | Stephen Boesch [Member]
Principal amount		250,000
Net proceeds from convertible debt		$ 500,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Cash equivalents
Unrealized gains or losses on investments in equity securities
Impairment losses on long-lived assets
Impairment losses on intangible assets
Impairment losses on goodwill
Revenues

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Fair Value Measurements (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Investments in equity securities, carrying value
Investments in equity securities		1,769,300
Convertible Series E Preferred Shares [Member] | Adhera Therapeutics [Member]
Investments in equity securities, carrying value
Investments in equity securities		1,769,300
Level 1 [Member]
Investments in equity securities
Level 1 [Member] | Convertible Series E Preferred Shares [Member] | Adhera Therapeutics [Member]
Investments in equity securities
Level 2 [Member]
Investments in equity securities
Level 2 [Member] | Convertible Series E Preferred Shares [Member] | Adhera Therapeutics [Member]
Investments in equity securities
Level 3 [Member]
Investments in equity securities		1,769,300
Level 3 [Member] | Convertible Series E Preferred Shares [Member] | Adhera Therapeutics [Member]
Investments in equity securities		$ 1,769,300

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Changes in Fair Value Measurements (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Opening Balance	$ 1,769,300
Closing balance		$ 1,769,300
Level 3 [Member]
Opening Balance	1,769,300
Value introduced		1,769,300
Write off value of investment	(1,769,300)
Closing balance		$ 1,769,300

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Potentially dilutive securities	35,660,831	31,166,510
Convertible Notes [Member]
Potentially dilutive securities	10,000,000
Stock Options [Member]
Potentially dilutive securities	6,145,044	6,785,617
Warrants [Member]
Potentially dilutive securities	19,515,787	24,380,893

Acquisitions (Details Narrative

Acquisitions (Details Narrative) - USD ($)	Nov. 04, 2019	Apr. 23, 2019	Apr. 22, 2019	Dec. 31, 2019	Dec. 31, 2018	Apr. 21, 2019
Common stock, par value				$ 0.01	$ 0.01
Common stock, shares issued				84,069,967	6,843,802
Common stock, shares outstanding				84,069,967	6,843,802
Number of preferred stock for acquisitions, value					$ 819,191
Shareholders [Member]
Common stock, shares outstanding						41,419,934
Equity ownership percentage			15.00%
Stock price			$ 0.09
Common Stock [Member]
Conversion of shares				80,772
Shares issued during the period				20,750	60,000
Number of preferred stock for acquisitions					204,796
Number of preferred stock for acquisitions, value					$ 2,048
Merger Agreement [Member]
Conversion of shares			10,318,746
Common stock, shares issued		82,419,967	41,419,934
Common stock, shares outstanding		82,419,967	41,419,934
Merger Agreement [Member] | PointR [Member]
Stock price	$ 0.18
Conversion of stock, value	$ 200,000
Conversion of stock, shares	84,475
Purchase price	$ 17,865,792
Consideration transferred	15,200,000
Contingent consideration	$ 2,600,000
Number of preferred stock for acquisitions	84,475
Number of preferred stock for acquisitions, value	$ 15,000,000
Repayment of short term debt	200,000
Merger Agreement [Member] | Shareholders [Member] | PointR [Member]
Purchase price	17,831,427
Contingent consideration	$ 2,625,000
Merger Agreement [Member] | Security Holders [Member] | PointR [Member]
Equity ownership percentage	23.29%
Merger Agreement [Member] | Stockholders [Member] | PointR [Member]
Equity ownership percentage	76.71%
Merger Agreement [Member] | Contingent Value Right [Member]
Percentage of net proceeds from merger			75.00%
Net proceeds from merger			$ 500,000
Merger Agreement [Member] | Oncotelic [Member]
Conversion of shares			41,000,033
Common stock, shares outstanding			10,318,746
Merger Agreement [Member] | Oncotelic [Member] | Former Shareholders [Member]
Shares to be issued during period preferred stock			10,000
Merger Agreement [Member] | Oncotelic [Member] | Converted Options [Member]
Conversion of shares			3,102,411
Merger Agreement [Member] | Oncotelic [Member] | Converted Warrants [Member]
Conversion of shares			150,000
Merger Agreement [Member] | Series A Preferred Stock [Member]
Conversion of shares			0.01877292
Merger Agreement [Member] | Series A Preferred Stock [Member] | Oncotelic [Member]
Conversion of shares			193,713
Shares issued during the period			77,154
Merger Agreement [Member] | Series A Convertible Preferred Stock [Member]
Conversion of shares			0.01877292
Merger Agreement [Member] | Series A Convertible Preferred Stock [Member] | Oncotelic [Member]
Conversion of shares		193,713	193,713
Shares issued during the period			77,154
Stock issued preferred stock conversion basis		preferred stock which converted at a 1:1,000 ratio
Merger Agreement [Member] | Common Stock [Member]
Common stock, par value			$ 0.01
Conversion of shares		193,712,995	3.97335267
Conversion of shares, par value			$ 0.01
Merger Agreement [Member] | Common Stock [Member] | PointR [Member]
Equity ownership percentage	23.29%
Stock price	$ 0.18
Conversion of stock, shares	1,000
Number of preferred stock for acquisitions	84,474,854
Number of preferred stock for acquisitions, value	$ 15,205,473
Common stock equivalents	$ 360,638,491
Merger Agreement [Member] | Common Stock [Member] | Oncotelic [Member]
Conversion of shares			1,000
Common stock, shares outstanding			7,866,335
Merger Agreement [Member] | Common Stock [Member] | Oncotelic [Member] | Former Shareholders [Member]
Shares issued during the period			2,100,000
Merger Agreement [Member] | Preferred Stock [Member] | PointR [Member]
Conversion of stock, shares	1,000
Contingent consideration	$ 2,600,000
Number of preferred stock for acquisitions	84,475

Acquisitions - Schedule of Fair

Acquisitions - Schedule of Fair Values of Assets Acquired and Liabilities Assumed (Details) - USD ($)		Dec. 31, 2019	Nov. 04, 2019	Apr. 22, 2019	Dec. 31, 2018
Goodwill		$ 21,062,455
Merger Agreement [Member] | Oncotelic, Inc. [Member]
Cash				$ 182,883
Prepaid expense				56,175
Accounts payable and other current liabilities assumed				(1,391,302)
Net assets/ liability acquired				(1,152,244)
Goodwill	[1]			4,879,999
Total purchase price	[2]			$ 3,727,755
Merger Agreement [Member] | PointR [Member]
Cash			$ 6,403
Fixed Assets			56,792
Other assets assumed (excluding cash and fixed assets)			260,905
In-process research and development			1,377,200
Liabilities assumed			(17,964)
Net assets/ liability acquired			1,683,336
Goodwill			16,182,456
Total purchase price			$ 17,865,792
[1]	The primary items that generate goodwill include the value of the synergies between the acquired company and Oncotelic, Inc. and the acquired assembled workforce, neither of which qualifies for recognition as an intangible asset. Goodwill is the excess of the purchase price over the fair value of the underlying net tangible and identifiable intangible assets. In accordance with applicable accounting standards, goodwill is not amortized but instead is tested for impairment at least annually or more frequently if certain indicators are present. Goodwill and intangibles is not deductible for tax purposes. The Company has considered the valuation as a preliminary allocation of assets and liabilities and may adjust such estimates in the future, if deemed material.
[2]	The total purchase price of $3,727,755 represents the consideration transferred from Mateon in the Merger and was calculated based on the number of shares of Common Stock outstanding at the date of the Merger.

Acquisitions - Schedule of Fa_2

Acquisitions - Schedule of Fair Values of Assets Acquired and Liabilities Assumed (Details) (Parenthetical)	Apr. 22, 2020USD ($)
Merger Agreement [Member] | Oncotelic, Inc. [Member]
Consideration transferred	$ 3,727,755

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill (Details Narrative) - USD ($)	Nov. 04, 2019	Apr. 30, 2017	Dec. 31, 2019	Dec. 31, 2018	Apr. 22, 2019
Goodwill			$ 21,062,455
Shares issued during the period for acquisition				819,191
Amortization of identifiable intangible assets			$ 51,419	34,189
Merger Agreement [Member] | PointR [Member]
Goodwill	$ 16,182,456
Shares issued during the period for acquisition, shares	84,475
Shares issued during the period for acquisition	$ 15,000,000
Merger Agreement [Member] | Oncotelic [Member]
Goodwill					$ 4,751,055
Assignment and Assumption Agreement [Member] | Oncotelic [Member]
Previously billed charges wrote off				$ 458,000
Assignment and Assumption Agreement [Member] | Autotelic Inc., [Member]
Shares issued during the period for acquisition, shares		204,798
Shares issued during the period for acquisition		$ 819,191

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Schedule of Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Intangible asset, gross	$ 1,010,180	$ 1,010,180
Less Accumulated Amortization	(85,608)	(34,189)
Intangible asset, net	924,572	975,991
Intellectual Property [Member]
Intangible asset, gross	$ 819,191	$ 819,191
Remaining estimated useful life (years)	18 years 8 months 5 days	19 years 3 months 8 days
Capitalization of License Cost [Member]
Intangible asset, gross	$ 190,989	$ 190,989
Remaining estimated useful life (years)	18 years 8 months 5 days	19 years 3 months 8 days
In Process Research and Development [Member]
Intangible asset, gross	$ 1,377,200
Intangible asset, net	$ 1,377,200

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Schedule of Amortization of Expense for Intangible Assets (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
2020	$ 51,365
2021	51,365
2022	51,365
2023	51,365
2024	51,365
Thereafter	667,747
Intangible asset, net	$ 924,572	$ 975,991

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Accounts payable	$ 1,793,033
Accrued expense	261,950
Accounts payable and accrued liabilities	2,054,983
Accounts payable - related party	$ 601,682	$ 283,030

Convertible Debentures and No_3

Convertible Debentures and Notes (Details Narrative) - USD ($)

May 14, 2020

Dec. 11, 2019

Nov. 23, 2019

Nov. 05, 2019

Nov. 04, 2019

Aug. 06, 2019

Jul. 22, 2019

Jun. 12, 2019

Apr. 23, 2019

Apr. 17, 2019

Mar. 31, 2020

Feb. 29, 2020

May 10, 2020

Nov. 23, 2020

Dec. 31, 2019

Dec. 31, 2018

Debt Instrument [Line Items]

Convertible notes gross

$ 1,000,000

Initial debt discount

800,140

Amortization expense related to debt discount

155,644

Total unamortized debt discount

1,039,076

Deferred financing costs

53,052

0

Net proceeds from convertible debt

1,884,000

Amortization of OID and debt issuance costs

745,973

Non-cash compensation expense

340,674

80,000

Chance in fair value of derivative liability

191,643

Convertible note payable

800,000

Series A Preferred Stock [Member] | PointR Shareholders [Member]

Debt Instrument [Line Items]

Accrued interest

$ 4,603

Shares conversion

84,475

Fall 2019 Debt Financing [Member]

Debt Instrument [Line Items]

Gross proceeds from convertible debt

$ 1,000,000

Additional gross proceeds from convertible debt

$ 500,000

Convertible Debt [Member] | Bridge Investor [Member]

Debt Instrument [Line Items]

Total unamortized debt discount

$ 3,556

Principal amount

35,556

Net proceeds from convertible debt

32,000

Convertible Debt [Member] | Bridge Investor [Member] | Tranche 2 [Member]

Debt Instrument [Line Items]

Total unamortized debt discount

173,175

Derivative liability

541,000

Beneficial conversion feature, total

563,000

Original issue discount

169,000

Net proceeds from convertible debt

$ 26,825

Percentage of conversion price, description

As as such, Peak One, the CEO and the bridge investor had the ability to convert that debt into equity at the variable conversion price of 65% % of the Company's lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company's traded stock price under certain circumstances.

Chance in fair value of derivative liability

$ 192,000

Securities Purchase Agreement [Member] | Convertible Debt [Member] | Bridge Investor [Member] | Tranche 2 [Member]

Debt Instrument [Line Items]

Principal amount

$ 200,000

Maturity date

Aug. 6, 2022

Original issue discount

$ 20,000

Deferred financing costs

5,000

Net proceeds from convertible debt

$ 175,000

Percentage of conversion price, description

At a conversion price of $0.10 per share (the "Fixed Price"), at the lower of the Fixed Price or 65% of the Company's lowest traded price after the 180th day or at the lower of the Fixed Price or 55% of the Company's traded stock price under certain circumstances. The Company may redeem the Convertible Note at rates of 110% to 140% rates over the principal balance dependent on certain events and redeem the value with accrued interest thereon, if any.

Securities Purchase Agreement [Member] | Convertible Debt [Member] | Bridge Investor [Member] | Tranche One [Member]

Debt Instrument [Line Items]

Total unamortized debt discount

24,643

Beneficial conversion feature, total

28,445

Principal amount

$ 35,556

Maturity date

Apr. 23, 2022

Original issue discount

$ 3,556

Net proceeds from convertible debt

$ 32,000

7,358

Percentage of conversion price, description

(i) a conversion price, during the first 180 days, of $0.10 per share (the "Fixed Price"), and then (2) at the lower of the Fixed Price or 65% of the Company's lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company's traded stock price under certain circumstances. The Company may redeem the Convertible Note at rates of 110% to 140% rates over the principal balance dependent on certain events and redeem the value with accrued interest thereon, if any.

Securities Purchase Agreement [Member] | Convertible Debt [Member] | Vuong Trieu [Member]

Debt Instrument [Line Items]

Total unamortized debt discount

$ 113,970

Beneficial conversion feature, total

$ 131,555

Principal amount

$ 164,444

Maturity date

Apr. 23, 2022

Original issue discount, percentage

10.00%

10.00%

Original issue discount

$ 16,444

Net proceeds from convertible debt

$ 148,000

Percentage of conversion price, description

At the lower of the Fixed Price or 65% of the Company's lowest traded price after the 180th day or at the lower of the Fixed Price or 55% of the Company's traded stock price under certain circumstances.

Amortization of OID and debt issuance costs

$ 34,029

Securities Purchase Agreement [Member] | Convertible Debt [Member] | Maximum [Member] | Bridge Investor [Member]

Debt Instrument [Line Items]

Principal amount

$ 400,000

Securities Purchase Agreement [Member] | Convertible Debt [Member] | Maximum [Member] | Bridge Investor [Member] | Tranche 2 [Member]

Debt Instrument [Line Items]

Percentage of charge on penalty

40.00%

Percentage of redemption of convertible note

140.00%

Securities Purchase Agreement [Member] | Convertible Debt [Member] | Maximum [Member] | Bridge Investor [Member] | Tranche One [Member]

Debt Instrument [Line Items]

Percentage of charge on penalty

40.00%

Percentage of redemption of convertible note

140.00%

Securities Purchase Agreement [Member] | Convertible Debt [Member] | Maximum [Member] | Vuong Trieu [Member]

Debt Instrument [Line Items]

Percentage of charge on penalty

40.00%

Percentage of redemption of convertible note

140.00%

Securities Purchase Agreement [Member] | Convertible Debt [Member] | Minimum [Member] | Bridge Investor [Member] | Tranche 2 [Member]

Debt Instrument [Line Items]

Percentage of charge on penalty

18.00%

Percentage of redemption of convertible note

110.00%

Securities Purchase Agreement [Member] | Convertible Debt [Member] | Minimum [Member] | Bridge Investor [Member] | Tranche One [Member]

Debt Instrument [Line Items]

Percentage of charge on penalty

18.00%

Percentage of redemption of convertible note

110.00%

Securities Purchase Agreement [Member] | Convertible Debt [Member] | Minimum [Member] | Vuong Trieu [Member]

Debt Instrument [Line Items]

Percentage of charge on penalty

18.00%

Percentage of redemption of convertible note

110.00%

Note Purchase Agreements [Member] | Fall 2019 Notes [Member]

Debt Instrument [Line Items]

Total unamortized debt discount

200,000

Debt instrument, conversion description

(a) into shares of the Company's Common Stock at a conversion price of $0.18 per share, or (b) into shares of EdgePoint's, the Company's to be newly formed subsidiary for AI/Blockchain in pharmaceutical manufacturing, common stock at a conversion price of $5.00 (based on a $5 million pre-money valuation) of EdgePoint and 1 million shares outstanding.

Beneficial conversion feature, total

222,222

Amortization of OID and debt issuance costs

22,222

Debt interest rate

5.00%

Description on debt instrument

All amounts outstanding under the Fall 2019 Notes become due and payable upon the approval of the holders of a majority of the principal amount of outstanding Fall 2019 Notes (the "Majority Holders") on or after (a) November 23, 2020 or (b) the occurrence of an event of default (either, the "Maturity Date"). The Company may prepay the Fall 2019 Notes at any time. Events of default under the Fall 2019 Notes include failure to make payments under the Fall 2019 Notes within thirty (30) days of the date due, failure to observe of the Note Purchase Agreement or Fall 2019 Notes which is not cured within thirty (30) days of notice of the breach, bankruptcy, or a change in control of the Company (as defined in the Note Purchase Agreement).

Interest expense

$ 3,869

Note Purchase Agreements [Member] | Fall 2019 Notes [Member] | Dr. Vuong Trieu [Member]

Debt Instrument [Line Items]

Principal amount

$ 250,000

Gross proceeds from convertible debt

500,000

Due to related parties

35,000

Note Purchase Agreements [Member] | Fall 2019 Notes [Member] | Stephen Boesch [Member]

Debt Instrument [Line Items]

Principal amount

250,000

Gross proceeds from convertible debt

$ 500,000

Note Purchase Agreements [Member] | Fall 2019 Notes [Member] | Dr. Sanjay Jha [Member]

Debt Instrument [Line Items]

Principal amount

250,000

Note Purchase Agreements [Member] | Fall 2019 Notes [Member] | Chulho Park [Member]

Debt Instrument [Line Items]

Due to related parties

27,000

Note Purchase Agreements [Member] | Fall 2019 Notes [Member] | Amit Shah [Member]

Debt Instrument [Line Items]

Due to related parties

20,000

Note Purchase Agreements [Member] | Fall 2019 Notes [Member] | Two Affiliates [Member]

Debt Instrument [Line Items]

Principal amount

$ 168,000

Peak One Opportunity Fund, L.P [Member] | Subsequent Event [Member]

Debt Instrument [Line Items]

Conversion of debt, shares

2,012,145

Conversion of debt, amount

$ 400,000

$ 400,000

$ 150,000

Peak One Opportunity Fund, L.P [Member] | Convertible Debt [Member] | Tranche One [Member]

Debt Instrument [Line Items]

Maturity date

Jan. 18, 2020

Conversion of debt, shares

3,000

Common stock percentage

65.00%

Conversion price per share

$ 0.10

Non-cash compensation expense

$ 60,000

Peak One Opportunity Fund, L.P [Member] | Securities Purchase Agreement [Member] | Convertible Debt [Member]

Debt Instrument [Line Items]

Total unamortized debt discount

84,377

Beneficial conversion feature, total

84,570

Principal amount

200,000

Aggregate purchase price

$ 400,000

Number of restricted stock issued

350,000

Maturity date

Apr. 23, 2022

Original issue discount, percentage

10.00%

Original issue discount

$ 20,000

Deferred financing costs

5,000

Net proceeds from convertible debt

$ 175,000

Conversion of shares, par value

$ 0.10

Percentage of conversion price, description

(i) a conversion price, during the first 180 days, of $0.10 per share (the "Fixed Price"), and then (2) at the lower of the Fixed Price or 65% of the Company's lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company's traded stock price under certain circumstances. The Company has agreed, to at all times, reserve and keep available out of its authorized common stock a number of shares equal to at least two times the full number of the Tranche #1 Conversion Shares. The Company may redeem the Convertible Note at rates of 110% to 140% over the principal balance dependent on certain events and redeem the value with accrued interest thereon, if any.

Beneficial conversion feature, excluding discount

$ 52,285

Number of restricted stock issued, value

32,285

Amortization of OID and debt issuance costs

25,193

Peak One Opportunity Fund, L.P [Member] | Securities Purchase Agreement [Member] | Convertible Debt [Member] | Tranche One [Member]

Debt Instrument [Line Items]

Principal amount

200,000

Peak One Opportunity Fund, L.P [Member] | Securities Purchase Agreement [Member] | Convertible Debt [Member] | Third Tranche [Member]

Debt Instrument [Line Items]

Principal amount

$ 200,000

Peak One Opportunity Fund, L.P [Member] | Securities Purchase Agreement [Member] | Convertible Debt [Member] | Tranche Two [Member]

Debt Instrument [Line Items]

Total unamortized debt discount

163,954

Beneficial conversion feature, total

180,000

Principal amount

$ 200,000

Number of restricted stock issued

350,000

Maturity date

Jun. 12, 2022

Original issue discount, percentage

10.00%

Original issue discount

$ 20,000

Deferred financing costs

1,000

Net proceeds from convertible debt

179,000

Beneficial conversion feature, excluding discount

132,091

Number of restricted stock issued, value

47,909

Amortization of OID and debt issuance costs

37,046

Peak One Opportunity Fund, L.P [Member] | Securities Purchase Agreement [Member] | Convertible Debt [Member] | Maximum [Member]

Debt Instrument [Line Items]

Principal amount

$ 400,000

Percentage of charge on penalty

40.00%

Percentage of redemption of convertible note

140.00%

Peak One Opportunity Fund, L.P [Member] | Securities Purchase Agreement [Member] | Convertible Debt [Member] | Maximum [Member] | Tranche One [Member]

Debt Instrument [Line Items]

Principal amount

$ 600,000

Peak One Opportunity Fund, L.P [Member] | Securities Purchase Agreement [Member] | Convertible Debt [Member] | Minimum [Member]

Debt Instrument [Line Items]

Percentage of charge on penalty

18.00%

Percentage of redemption of convertible note

110.00%

TFK Investments, LLC [Member] | Subsequent Event [Member]

Debt Instrument [Line Items]

Conversion of debt, shares

1,950,000

1,950,000

Conversion of debt, amount

$ 200,000

$ 133,430

Due to related parties

$ 66,570

TFK Investments, LLC [Member] | Securities Purchase Agreement [Member] | Convertible Debt [Member]

Debt Instrument [Line Items]

Total unamortized debt discount

84,377

Beneficial conversion feature, total

$ 84,570

Principal amount

$ 200,000

Number of restricted stock issued

350,000

Maturity date

Jan. 8, 2020

Apr. 23, 2022

Original issue discount, percentage

10.00%

Original issue discount

$ 20,000

Deferred financing costs

5,000

Net proceeds from convertible debt

$ 175,000

Conversion of shares, par value

$ 0.10

Percentage of conversion price, description

(i) a conversion price, during the first 180 days, of $0.10 per share (the "Fixed Price"), and then (2) at the lower of the Fixed Price or 65% of the Company's lowest traded price after the first 180 days or at the lower of the Fixed Price or 55% of the Company's traded stock price under certain circumstances. The Company has agreed to at all times reserve and keep available out of its authorized common stock a number of shares equal to at least two times the full number of the TFK Conversion Shares. The Company may redeem the Convertible Note at rates of 110% to 140% rates over the principal balance dependent on certain events and redeem the value with accrued interest thereon, if any.

Beneficial conversion feature, excluding discount

$ 52,285

Number of restricted stock issued, value

$ 32,285

Amortization of OID and debt issuance costs

$ 25,193

Conversion of debt, shares

300,000

Common stock percentage

65.00%

Conversion price per share

$ 0.10

Non-cash compensation expense

$ 60,000

TFK Investments, LLC [Member] | Securities Purchase Agreement [Member] | Convertible Debt [Member] | Maximum [Member]

Debt Instrument [Line Items]

Percentage of charge on penalty

40.00%

Percentage of redemption of convertible note

140.00%

TFK Investments, LLC [Member] | Securities Purchase Agreement [Member] | Convertible Debt [Member] | Minimum [Member]

Debt Instrument [Line Items]

Percentage of charge on penalty

18.00%

Percentage of redemption of convertible note

110.00%

PointR Data, Inc [Member] | Convertible Debt [Member]

Debt Instrument [Line Items]

Principal amount

$ 200,000

Maturity date

Jan. 1, 2020

Net proceeds from convertible debt

$ 10,000,000

Debt interest rate

8.00%

Debt instrument, payment terms

Interest payments were due monthly on the 15th day of each calendar month (or the next business day thereafter), and were payable, at the option of the holder, either in cash or in shares of the Company's Common Stock, valued at the closing price of the Common Stock on the principal market on which the Common Stock is either traded or quoted at such time. The Convertible Promissory Note was due and payable on demand by the holder (a) at any time after January 1, 2020 or (b) upon the occurrence of an Event of Default (as defined in the Convertible Note and the Note Purchase Agreement).

Convertible Debentures and No_4

Convertible Debentures and Notes - Schedule of Convertible Debentures (Details)	Dec. 31, 2019USD ($)
Convertible note payable	$ 160,924
10% Convertible Note Payable, Due April 23, 2022 [Member] | Bridge Investor [Member]
Convertible note payable	(2,748)
10% Convertible Note Payable, Due April 23, 2022 [Member] | Related Party [Member]
Convertible note payable	(12,663)
10% Convertible Note Payable, Due April 23, 2022 [Member] | Peak One [Member]
Convertible note payable	115,623
10% Convertible Note Payable, Due April 23, 2022 [Member] | TFK Investments, LLC [Member]
Convertible note payable	115,623
10% Convertible Note Payable, Due June 12, 2022 [Member] | Peak One Opportunity Fund, L.P [Member]
Convertible note payable	(81,735)
10% Convertible Note Payable, Due August 6, 2022 [Member] | Bridge Investor [Member]
Convertible note payable	$ 26,824

Convertible Debentures and No_5

Convertible Debentures and Notes - Schedule of Convertible Debentures (Details) (Parenthetical)	Dec. 31, 2019
10% Convertible Note Payable, Due April 23, 2022 [Member] | Bridge Investor [Member]
Interest rate	10.00%
10% Convertible Note Payable, Due April 23, 2022 [Member] | Related Party [Member]
Interest rate	10.00%
10% Convertible Note Payable, Due April 23, 2022 [Member] | Peak One [Member]
Interest rate	10.00%
10% Convertible Note Payable, Due April 23, 2022 [Member] | TFK Investments, LLC [Member]
Interest rate	10.00%
10% Convertible Note Payable, Due June 12, 2022 [Member] | Peak One [Member]
Interest rate	10.00%
10% Convertible Note Payable, Due August 6, 2022 [Member] | Bridge Investor [Member]
Interest rate	10.00%

Convertible Debentures and No_6

Convertible Debentures and Notes - Schedule of Accrued Interest (Details)	Dec. 31, 2019USD ($)
Convertible note payable	$ 800,000
5% Convertible note payable - Stephen Boesch [Member]
Convertible note payable	187,785
5% Convertible note payable - Vuong Trieu [Member]
Convertible note payable	187,785	[1]
5% Convertible note payable - Sanjay Jha (Through his family trust) [Member]
Convertible note payable	187,785
5% Convertible note payable - CEO, CTO & CFO [Member]
Convertible note payable	77,620
5% Convertible note payable - Bridge Investors [Member]
Convertible note payable	$ 159,025
[1]	There was an amount of $130,000 due for the Note from Dr. Trieu as of December 31, 2019. Such amount was received by the Company during the three months ended March 31, 2020.

Convertible Debentures and No_7

Convertible Debentures and Notes - Schedule of Accrued Interest (Details) (Parenthetical)	Dec. 31, 2019USD ($)
5% Convertible note payable - Stephen Boesch [Member]
Interest rate	5.00%
5% Convertible note payable - Vuong Trieu [Member]
Interest rate	5.00%
Due from related party	$ 130,000
5% Convertible note payable - Sanjay Jha (Through his family trust) [Member]
Interest rate	5.00%
5% Convertible note payable - CEO, CTO & CFO [Member]
Interest rate	5.00%
5% Convertible note payable - Bridge Investors [Member]
Interest rate	5.00%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Dec. 26, 2019	Apr. 23, 2019	Dec. 31, 2018	Apr. 13, 2018	Jan. 31, 2019	Dec. 31, 2018	Dec. 31, 2015	Dec. 31, 2019	Dec. 31, 2018
Number of shares issued during the period, value								$ 83,000	$ 240,000
Unamortized intangible assets			$ 1,010,180			$ 1,010,180		1,010,180	1,010,180
Net proceeds from convertible debt								1,884,000
Chief Executive Officer [Member] | Fall 2019 Note [Member]
Principal amount		$ 250,000
Debt conversion amount		35,000
Chief Executive Officer [Member] | Convertible Debt [Member]
Principal amount		164,444
Net proceeds from convertible debt		148,000
Autotelic Inc., [Member]
Shares issued price per share					$ 4
Autotelic Inc., [Member] | Trabedersen License [Member]
Number of shares issued during the period			204,798
Payment to acquire licenses				$ 819,191			$ 395,150
License term							5 years
Payment of remaining prepaid expenses				$ 191,191
Amortization of acquired intangibles								51,365	34,243
Unamortized intangible assets			$ 975,991			$ 975,991		924,572	975,991
Master Service Agreement [Member] | Autotelic Inc., [Member]
Agreement related expenses								1,280,737	1,029,439
Number of shares issued during the period					80,772
Shares issued price per share					$ 4
Charges incurred								$ 48,485	$ 0
Master Service Agreement [Member] | Autotelic Inc., [Member] | Vuong Trieu [Member]
Termination agreement, description								The MSA requires a 90-day written termination notice in the event either party requires to terminate such services.
Master Service Agreement [Member] | Autotelic Inc., [Member] | Vuong Trieu [Member] | Maximum [Member]
Equity ownership percentage								10.00%
Stock Purchase Agreement [Member] | Autotelic Inc., [Member]
Number of shares issued during the period						226,988
Shares issued price per share			$ 4			$ 4			$ 4
Stock Purchase Agreement [Member] | Autotelic Inc., [Member] | Convertible Series E Preferred Shares [Member]
Number of shares issued during the period						181.59
Number of shares issued during the period, value						$ 907,950
Stock Purchase Agreement [Member] | Oncotelic [Member] | Vuong Trieu [Member]
Number of shares issued during the period	189,238
Shares issued price per share	$ 4
Stock Purchase Agreement [Member] | Oncotelic [Member] | Vuong Trieu [Member]
Number of shares issued during the period						189,238
Shares issued price per share			$ 4			$ 4			$ 4
Stock Purchase Agreement [Member] | Oncotelic [Member] | Vuong Trieu [Member] | Convertible Series E Preferred Shares [Member]
Number of shares issued during the period						151.39
Number of shares issued during the period, value						$ 756,950
Securities Purchase Agreement [Member] | Vuong Trieu [Member] | Convertible Debt [Member]
Principal amount		164,444
Original issue discount		16,444
Net proceeds from convertible debt		$ 148,000

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)

Dec. 26, 2019

Nov. 18, 2019

Jun. 12, 2019

Apr. 23, 2019

Apr. 22, 2019

Jan. 11, 2019

Apr. 30, 2019

Mar. 31, 2019

Jan. 31, 2019

Dec. 31, 2018

Dec. 31, 2019

Dec. 31, 2018

Number of shares issued during the period, value

$ 83,000

$ 240,000

Common shares issued for settlement of accounts payable

238,090

Common shares issued in conversion of warrants

$ 120

Autotelic Inc., [Member]

Shares issued price per share

$ 4

Common shares issued for settlement of accounts payable

$ 80,772

Peak One Opportunity Fund, L.P [Member] | Restricted Shares [Member]

Number of shares issued during the period

300,000

Number of shares issued during the period, value

$ 60,000

Shares issued price per share

$ 0.20

Conversion percentage

65.00%

Conversion maturity date

Jan. 18, 2020

Conversion price per share

$ 0.10

TFK Investments, LLC [Member] | Restricted Shares [Member]

Number of shares issued during the period

300,000

Number of shares issued during the period, value

$ 60,000

Shares issued price per share

$ 0.20

Conversion percentage

65.00%

Conversion maturity date

Jan. 8, 2020

Conversion price per share

$ 0.10

Employee [Member] | Oncotelic [Member]

Shares issued price per share

$ 4

$ 4

Common shares issued for compensation

$ 11,250

$ 80,594

Two Separates Investors [Member] | Oncotelic [Member]

Number of shares issued during the period

20,750

Number of shares issued during the period, value

$ 83,000

Shares issued price per share

$ 4

Two Investors [Member]

Common shares issued in conversion of warrants

$ 150,000

Common shares issued in conversion of warrants, shares

120

Stock Purchase Agreement [Member] | Oncotelic [Member] | Autotelic Inc., [Member]

Number of shares issued during the period

226,988

Shares issued price per share

$ 4

Stock Purchase Agreement [Member] | Adhera Therapeutics [Member] | Convertible Series E Preferred Shares [Member] | Autotelic Inc., [Member]

Number of shares issued during the period

181.59

Number of shares issued during the period, value

$ 907,950

Stock Purchase Agreement [Member] | Autotelic Inc., [Member]

Number of shares issued during the period

226,988

Shares issued price per share

$ 4

$ 4

Stock Purchase Agreement [Member] | Autotelic Inc., [Member] | Convertible Series E Preferred Shares [Member]

Number of shares issued during the period

181.59

Number of shares issued during the period, value

$ 907,950

Stock Purchase Agreement [Member] | Third-Party Investor [Member] | Oncotelic [Member]

Number of shares issued during the period

26,100

Stock Purchase Agreement [Member] | Third-Party Investor [Member] | Adhera Therapeutics [Member] | Convertible Series E Preferred Shares [Member]

Number of shares issued during the period

20.88

Number of shares issued during the period, value

$ 104,400

Stock Purchase Agreement [Member] | Vuong Trieu [Member] | Oncotelic [Member]

Number of shares issued during the period

189,238

Shares issued price per share

$ 4

Stock Purchase Agreement [Member] | Vuong Trieu [Member] | Adhera Therapeutics [Member] | Convertible Series E Preferred Shares [Member]

Number of shares issued during the period

151.39

Number of shares issued during the period, value

$ 756,950

Merger Agreement [Member]

Conversion of shares

10,318,746

Merger Agreement [Member] | Convertible Debt [Member]

Number of restricted stock issued during the period

350,000

Merger Agreement [Member] | Series A Preferred Stock [Member]

Conversion of shares

0.01877292

Merger Agreement [Member] | Series A Convertible Preferred Stock [Member]

Conversion of shares

0.01877292

Merger Agreement [Member] | Oncotelic [Member]

Conversion of shares

41,000,033

Merger Agreement [Member] | Oncotelic [Member] | Series A Preferred Stock [Member]

Number of shares issued during the period

77,154

Conversion of shares

193,713

Merger Agreement [Member] | Oncotelic [Member] | Series A Convertible Preferred Stock [Member]

Number of shares issued during the period

77,154

Conversion of shares

193,713

193,713

Merger Agreement [Member] | PointR [Member] | Series A Convertible Preferred Stock [Member]

Number of shares issued during the period

84,475

Conversion of shares

11,135,935

Merger Agreement [Member] | Two Noteholders [Member] | Convertible Debt [Member]

Shares issued price per share

$ 0.18

$ 0.11

Number of restricted stock issued during the period

700,000

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	Apr. 22, 2019	Dec. 31, 2019	Dec. 31, 2019
Options exercisable term			10 years
Options vesting period			3 years
Aggregate intrinsic value of options		$ 0	$ 0
Weighted average fair value			$ 0.19
Share based compensation	$ 341,000
Number of hare-based payment award, accelerated vesting	328,000
Warrants excersiable term		6 months 29 days	6 months 29 days
Number of warrants issued during period
Maximum [Member]
Warrants excersiable term		5 years	5 years
Minimum [Member]
Warrants excersiable term		3 years	3 years
2017 Equity Incentive Plan [Member] | Maximum [Member]
Number of common stock issued to awards			2,000,000
2015 and 2005 Equity Incentive Plan [Member] | Maximum [Member]
Number of common stock issued to awards			7,250,000

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Compensation Based Stock Option Activity (Details)	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Compensation Related Costs [Abstract]
Options Outstanding, Beginning Balance | shares	6,785,617
Options Outstanding, Granted/Additions | shares
Options Outstanding, Exercised | shares
Options Outstanding, Expired or canceled | shares	(640,573)
Options Outstanding, Ending Balance | shares	6,145,044
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 0.75
Weighted Average Exercise Price, Granted/Additions | $ / shares
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Expired or canceled | $ / shares	0.62
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	$ 0.75

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Options to Purchase Shares of Common Stock Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Number of Outstanding Options	6,145,044
Weighted Average Remaining Life In Years	7 years 1 month 13 days
Weighted-Average Exercise Price | $ / shares	$ 0.75
Number Exercisable	6,145,044
Exercise Price One [Member]
Exercise Prices | $ / shares	$ 0.22
Number of Outstanding Options	2,524,513
Weighted Average Remaining Life In Years	8 years 5 months 23 days
Weighted-Average Exercise Price | $ / shares	$ 0.22
Number Exercisable	2,524,513
Exercise Price Two [Member]
Exercise Prices | $ / shares	$ 0.38
Number of Outstanding Options	1,162,500
Weighted Average Remaining Life In Years	7 years 15 days
Weighted-Average Exercise Price | $ / shares	$ 0.375
Number Exercisable	1,162,500
Exercise Price Three [Member]
Exercise Prices | $ / shares	$ 0.51
Number of Outstanding Options	242,966
Weighted Average Remaining Life In Years	7 years 5 months 12 days
Weighted-Average Exercise Price | $ / shares	$ 0.51
Number Exercisable	242,966
Exercise Price Four [Member]
Exercise Prices | $ / shares	$ 0.58
Number of Outstanding Options	271,224
Weighted Average Remaining Life In Years	6 years 9 months 25 days
Weighted-Average Exercise Price | $ / shares	$ 0.58
Number Exercisable	271,224
Exercise Price Five [Member]
Exercise Prices | $ / shares	$ 0.73
Number of Outstanding Options	1,025,000
Weighted Average Remaining Life In Years	6 years 2 months 23 days
Weighted-Average Exercise Price | $ / shares	$ 0.73
Number Exercisable	1,025,000
Exercise Price Six [Member]
Exercise Prices | $ / shares	$ 1.37
Number of Outstanding Options	150,000
Weighted Average Remaining Life In Years	5 years 6 months 21 days
Weighted-Average Exercise Price | $ / shares	$ 1.37
Number Exercisable	150,000
Exercise Price Seven [Member]
Exercise Prices | $ / shares	$ 1.43
Number of Outstanding Options	525,000
Weighted Average Remaining Life In Years	5 years 4 months 28 days
Weighted-Average Exercise Price | $ / shares	$ 1.43
Number Exercisable	525,000
Exercise Price Eight [Member]
Exercise Prices | $ / shares	$ 2.60
Number of Outstanding Options	5,280
Weighted Average Remaining Life In Years	4 years 6 months 3 days
Weighted-Average Exercise Price | $ / shares	$ 2.60
Number Exercisable	5,280
Exercise Price Nine [Member]
Exercise Prices | $ / shares	$ 2.79
Number of Outstanding Options	9,760
Weighted Average Remaining Life In Years	4 years 4 days
Weighted-Average Exercise Price | $ / shares	$ 2.79
Number Exercisable	9,760
Exercise Price Ten [Member]
Exercise Prices | $ / shares	$ 2.95
Number of Outstanding Options	150,000
Weighted Average Remaining Life In Years	4 years 4 months 17 days
Weighted-Average Exercise Price | $ / shares	$ 2.95
Number Exercisable	150,000
Exercise Price Eleven [Member]
Exercise Prices | $ / shares	$ 11.88
Number of Outstanding Options	2,359
Weighted Average Remaining Life In Years	2 years 4 days
Weighted-Average Exercise Price | $ / shares	$ 11.88
Number Exercisable	2,359
Exercise Price Twelve [Member]
Exercise Prices | $ / shares	$ 15
Number of Outstanding Options	75,000
Weighted Average Remaining Life In Years	5 years 4 months 28 days
Weighted-Average Exercise Price | $ / shares	$ 15
Number Exercisable	75,000
Exercise Price Thirteen [Member]
Exercise Prices | $ / shares	$ 19.80
Number of Outstanding Options	1,442
Weighted Average Remaining Life In Years	1 year 10 months 3 days
Weighted-Average Exercise Price | $ / shares	$ 19.80
Number Exercisable	1,442

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Warrants Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Compensation Related Costs [Abstract]
Number of Stock Options Outstanding, beginning balance	24,380,893	9,625,393
Number of Stock Options, Granted		16,362,500
Number of Stock Options, Expired or cancelled	(4,865,106)	(1,607,000)
Number of Stock Options Outstanding, ending balance	19,515,787	24,380,893
Weighted-Average Exercise Price, Outstanding, beginning balance	$ 1.05	$ 2.55
Weighted-Average Exercise Price, Granted		0.38
Weighted-Average Exercise Price, Expired or cancelled	2.82	3.35
Weighted-Average Exercise Price, Outstanding, ending balance	$ 0.60	$ 1.05

Stock-Based Compensation - Sc_4

Stock-Based Compensation - Schedule of Warrants Outstanding and Exercisable (Details)	Dec. 31, 2019$ / sharesshares
Warrants Outstanding, Number of Warrants	19,515,787
Warrants Exercisable, Weighted Average Remaining Life In Years	6 months 29 days
Warrants Weighted- Average Exercise Price | $ / shares	$ 0.60
Warrants Exercisable, Exercisable Number of Warrants	19,515,787
Exercise Price One [Member]
Warrants Outstanding, Exercise Price | $ / shares	$ 0.20
Warrants Outstanding, Number of Warrants	1,487,500
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 3 months 29 days
Warrants Weighted- Average Exercise Price | $ / shares	$ 0.20
Warrants Exercisable, Exercisable Number of Warrants	1,487,500
Exercise Price Two [Member]
Warrants Outstanding, Exercise Price | $ / shares	$ 0.40
Warrants Outstanding, Number of Warrants	14,875,000
Warrants Exercisable, Weighted Average Remaining Life In Years	4 months 17 days
Warrants Weighted- Average Exercise Price | $ / shares	$ 0.40
Warrants Exercisable, Exercisable Number of Warrants	14,875,000
Exercise Price Three [Member]
Warrants Outstanding, Exercise Price | $ / shares	$ 1.71
Warrants Outstanding, Number of Warrants	2,919,710
Warrants Exercisable, Weighted Average Remaining Life In Years	2 months 23 days
Warrants Weighted- Average Exercise Price | $ / shares	$ 1.71
Warrants Exercisable, Exercisable Number of Warrants	2,919,710
Exercise Price Four [Member]
Warrants Outstanding, Exercise Price | $ / shares	$ 2.13
Warrants Outstanding, Number of Warrants	233,577
Warrants Exercisable, Weighted Average Remaining Life In Years	2 months 19 days
Warrants Weighted- Average Exercise Price | $ / shares	$ 2.13
Warrants Exercisable, Exercisable Number of Warrants	233,577

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Net deferred tax assets	$ 65,000,000	$ 1,000,000
Net operating loss carry-forwards	$ 248,000,000
Net operating loss expiration year	2038

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)	Nov. 04, 2019USD ($)	Dec. 31, 2019USD ($)ft²$ / shares	Dec. 31, 2018USD ($)$ / shares
Lease expiration date		Jun. 30, 2019
Area of facility lease | ft²		5,275
Rental expense		$ 35,772	$ 35,772
Common stock par value | $ / shares		$ 0.01	$ 0.01
Contingent liability		$ 2,600,000
Merger Agreement [Member] | PointR Data, Inc [Member]
Purchase price consideration	$ 17,831,427
Contingent liability	$ 2,625,000
Restricted Shares [Member]
Common stock par value | $ / shares		$ 0.01

Commitments and Contingencies -

Commitments and Contingencies - Summary of Restricted Stock Grants and Stock Option Grants (Details)	12 Months Ended
	Dec. 31, 2019shares
Stock options
Vuong Trieu [Member] | Chief Executive Officer [Member]
Restricted stock	209,302
Stock options	313,953
Fatih Uckun [Member] | Chief Medical Officer [Member]
Restricted stock	186,047
Stock options	279,070
Chulho Park [Member] | Chief Technology Officer [Member]
Restricted stock	162,791
Stock options	244,186
Amit Shah [Member] | Chief Financial Officer [Member]
Restricted stock	148,837
Stock options	223,256

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	May 14, 2020	Apr. 21, 2020	Apr. 06, 2020	Mar. 31, 2020	Feb. 29, 2020	Mar. 31, 2020	May 10, 2020	Dec. 31, 2019	Dec. 31, 2018
Subsequent Event [Line Items]
Number of warrants cancelled								4,865,106	1,607,000
Number of warrants outstanding								19,515,787
Subsequent Event [Member] | Investors [Member]
Subsequent Event [Line Items]
Number of warrants cancelled						14,875,000
Warrant price, per share				$ 0.40		$ 0.40
Number of warrants outstanding				14,875,000		14,875,000
Number of warrants exchanges for new warrants						13,750,000
Subsequent Event [Member] | Investors [Member] | New Warrant [Member]
Subsequent Event [Line Items]
Warrant price, per share				$ 0.20		$ 0.20
Subsequent Event [Member] | Peak One Opportunity Fund, L.P [Member]
Subsequent Event [Line Items]
Conversion of debt				$ 400,000	$ 400,000		$ 150,000
Conversion of debt, shares							2,012,145
Subsequent Event [Member] | Peak One Opportunity Fund, L.P [Member] | TFK Investments, LLC [Member]
Subsequent Event [Line Items]
Original debt conversion amount				$ 150,000	$ 150,000
Conversion of debt, shares				2,012,145	2,012,145
Remaining unpaid balance	$ 250,000
Subsequent Event [Member] | TFK Investments, LLC [Member]
Subsequent Event [Line Items]
Original debt conversion amount	133,430
Conversion of debt	$ 200,000						$ 133,430
Conversion of debt, shares	1,950,000						1,950,000
Remaining unpaid balance	$ 66,570
Subsequent Event [Member] | Paycheck Protection Program [Member] | Silicon Valley Bank [Member]
Subsequent Event [Line Items]
Notes payable		$ 250,000
Maturity date		Apr. 21, 2022
Debt interest rate		1.00%
Subsequent Event [Member] | Research Service Agreement [Member]
Subsequent Event [Line Items]
Service fees			$ 1,200,000
Reimbursement cost			$ 100,000